Gefitinib (ZD1839)

Name: Gefitinib (ZD1839)
Brand: Selleck Chemicals
SKU: S1025
Rating: 5 (348 reviews)

For research use only.

Catalog No.S1025

348 publications

Molecular Weight(MW): 446.90

Gefitinib (ZD-1839) is an EGFR inhibitor for Tyr1173, Tyr992, Tyr1173 and Tyr992 in the NR6wtEGFR and NR6W cells with IC50 of 37 nM, 37nM, 26 nM and 57 nM, respectively. Gefitinib promotes autophagy and apoptosis of lung cancer cells via blockade of the PI3K/AKT/mTOR pathway.

Selleck's Gefitinib (ZD1839) has been cited by 348 publications

Cell Stem Cell, 2020, 7;26(5):782-792e7

PubMed: 32348727 ( click the link to review the publication )

Cancer Cell, 2020, 13;37(1):104-122e12

PubMed: 31935369 ( click the link to review the publication )

Cancer Discov, 2019, 9(7):926-943

PubMed: 31092401 ( click the link to review the publication )

Cell Stem Cell, 2019, 25(1):69-86

PubMed: 31080136 ( click the link to review the publication )

Cell, 2018, 172(1-2):373-386

PubMed: 29224780 ( click the link to review the publication )

Nat Med, 2018, 24(4):512-517

PubMed: 29505033 ( click the link to review the publication )

Nat Methods, 2018, 15(8):631-639

PubMed: 30038414 ( click the link to review the publication )

Cancer Cell, 2018, 34(3):427-438

PubMed: 30205045 ( click the link to review the publication )

Nature, 2017, 547(7664):453-457

PubMed: 28678785 ( click the link to review the publication )

Nature, 2016, 30;534(7609):647-51.

PubMed: 27338794 ( click the link to review the publication )

Nat Med, 2016, 22(3):262-9

PubMed: 26828195 ( click the link to review the publication )

Cancer Discov, 2015, 5(7):713-22

PubMed: 25934077 ( click the link to review the publication )

Cancer Discov, 2015, 5(9):960-971

PubMed: 26036643 ( click the link to review the publication )

Nature, 2014, 3;508(7494):118-22.

PubMed: 24670642 ( click the link to review the publication )

Nat Med, 2013, 19(11):1469-1472

PubMed: 24162815 ( click the link to review the publication )

Nature, 2012, 26;483(7387):100-3.

PubMed: 22281684 ( click the link to review the publication )

Cell, 2012, 21;151(5):937-50.

PubMed: 23178117 ( click the link to review the publication )

Cancer Discov, 2012, 2(10):934-47

PubMed: 22961667 ( click the link to review the publication )

Cancer Discov, 2011, 1(7):608-25

PubMed: 22586683 ( click the link to review the publication )

Acta Neuropathol, 2020, 17

PubMed: 32303840 ( click the link to review the publication )

Nat Commun, 2020, 21;11(1):1923

PubMed: 32317663 ( click the link to review the publication )

Nat Commun, 2020, 25;11(1):1556

PubMed: 32214092 ( click the link to review the publication )

Sci Adv, 2020, 6(11):eaax2271

PubMed: 32195335 ( click the link to review the publication )

Clin Cancer Res, 2020, 10.1158/1078-0432

PubMed: 32034078 ( click the link to review the publication )
Mol Syst Biol, 2020, 16(2):e8664

PubMed: 32073727 ( click the link to review the publication )

Aging Cell, 2020, 22:e13145

PubMed: 32323422 ( click the link to review the publication )

Cancer Lett, 2020, 475:109-118

PubMed: 32004572 ( click the link to review the publication )

Sci Signal, 2020, 3;13(621) pii: eaax2364

PubMed: 32127496 ( click the link to review the publication )

Cancers (Basel), 2020, 27;12(5)pii: E1087

PubMed: 32349331 ( click the link to review the publication )

Cancers (Basel), 2020, 13;12(2) pii: E436

PubMed: 32069833 ( click the link to review the publication )

Cancers (Basel), 2020, 12(2)

PubMed: 32045997 ( click the link to review the publication )

Cancers (Basel), 2020, 12(2)

PubMed: 32093123 ( click the link to review the publication )

Cell Death Dis, 2020, 11(2):143

PubMed: 32081857 ( click the link to review the publication )

Cancer Discov, 2020, 15 pii: CD-20-0116

PubMed: 32414908 ( click the link to review the publication )

Front Immunol, 2020, 10:3135

PubMed: 32082304 ( click the link to review the publication )

Mol Cancer Ther, 2020, 5 pii: molcanther

PubMed: 32371577 ( click the link to review the publication )

Mol Cell Proteomics, 2020, 31 pii: mcp

PubMed: 32234966 ( click the link to review the publication )

Neurobiol Dis, 2020, 9;104961

PubMed: 32531343 ( click the link to review the publication )

J Cancer, 2020, 6;11(13):3762-3770

PubMed: 32328181 ( click the link to review the publication )

Cancer Sci, 2020, 111(5):1652-1662

PubMed: 32133706 ( click the link to review the publication )

Biomolecules, 2020, 10(1)

PubMed: 31947839 ( click the link to review the publication )

Mol Cancer Res, 2020, 10.1158/1541-7786.MCR-19-0669

PubMed: 32238439 ( click the link to review the publication )

Mol Cancer Res, 2020, 25

PubMed: 32098826 ( click the link to review the publication )

Front Oncol, 2020, 9:1503

PubMed: 31993373 ( click the link to review the publication )

Front Oncol, 2020, 12;10:696

PubMed: 32528877 ( click the link to review the publication )

J Cell Mol Med, 2020, 24(10):5578-5592

PubMed: 32248643 ( click the link to review the publication )

J Cell Mol Med, 2020, 24(10):5811-5816

PubMed: 32281297 ( click the link to review the publication )

Sci Rep, 2020, 17;10(1):2735

PubMed: 32066763 ( click the link to review the publication )
Cancer Cell Int, 2020, 19;20:58

PubMed: 32099531 ( click the link to review the publication )

Biomed Pharmacother, 2020, 16;127:110225

PubMed: 32428834 ( click the link to review the publication )

Eur J Pharmacol, 2020, 5;874:172961

PubMed: 32044322 ( click the link to review the publication )

Thorac Cancer, 2020, 5

PubMed: 32368855 ( click the link to review the publication )

J Thorac Dis, 2020, 12(3):712-723

PubMed: 32274137 ( click the link to review the publication )

Int J Radiat Biol, 2020, 96(4):461-468

PubMed: 31859574 ( click the link to review the publication )

Cytometry A, 2020, 97(1):70-77

PubMed: 31411813 ( click the link to review the publication )

Exp Cell Res, 2020, 390(2):111950

PubMed: 32188578 ( click the link to review the publication )

J Thorac Oncol, 2020, 15(5):752-765

PubMed: 31972351 ( click the link to review the publication )

Nat Cell Biol, 2019, 21(6):778-790

PubMed: 31160710 ( click the link to review the publication )

Mol Cell, 2019, 73(1):166-182

PubMed: 30609389 ( click the link to review the publication )

Hepatology, 2019, 10.1002/hep.30780

PubMed: 31127639 ( click the link to review the publication )

Nat Commun, 2019, 10(1):2701

PubMed: 31221965 ( click the link to review the publication )

Nano Lett, 2019, 19(10):7526-7533

PubMed: 31487192 ( click the link to review the publication )

Nat Commun, 2019, 10(1):2919

PubMed: 31266962 ( click the link to review the publication )

Autophagy, 2019, 10.1080/15548627.2019.1660545

PubMed: 31462148 ( click the link to review the publication )

EMBO J, 2019, 38(4)

PubMed: 30643021 ( click the link to review the publication )

Cancer Res, 2019, 79(4):819-829

PubMed: 30573522 ( click the link to review the publication )

J Am Soc Nephrol, 2019, 30(8):1454-1470

PubMed: 31253651 ( click the link to review the publication )

Matrix Biol, 2019, 10.1016/j.matbio.2019.07.006

PubMed: 31323325 ( click the link to review the publication )

Cell Rep, 2019, 26(1):65-78

PubMed: 30605687 ( click the link to review the publication )

Int J Cancer, 2019, 10.1002/ijc.32487

PubMed: 31162839 ( click the link to review the publication )

Int J Cancer, 2019, 145(5):1432-1444

PubMed: 30784054 ( click the link to review the publication )

Oncogene, 2019, 38(14):2464-2481

PubMed: 30532069 ( click the link to review the publication )
Oncogene, 2019, 38(11):1936-1950

PubMed: 30390071 ( click the link to review the publication )

Oncogene, 2019, 38(37):6399-6413

PubMed: 31324888 ( click the link to review the publication )

J Exp Clin Cancer Res, 2019, 38(1):46

PubMed: 30709379 ( click the link to review the publication )

J Exp Clin Cancer Res, 2019, 38(1):96

PubMed: 30791926 ( click the link to review the publication )

J Exp Clin Cancer Res, 2019, 38(1):481

PubMed: 31801598 ( click the link to review the publication )

Cancers (Basel), 2019, 11(1)

PubMed: 30609749 ( click the link to review the publication )

Cancers (Basel), 2019, 11(10)

PubMed: 31635301 ( click the link to review the publication )

Breast Cancer Res, 2019, 21(1):77

PubMed: 31262335 ( click the link to review the publication )

Cell Death Dis, 2019, 10(4):283

PubMed: 30911072 ( click the link to review the publication )

Signal Transduct Target Ther, 2019, 4:25

PubMed: 31637005 ( click the link to review the publication )

Cells, 2019, 8(12)

PubMed: 31795298 ( click the link to review the publication )

Cell Physiol Biochem, 2019, 53(5):805-819

PubMed: 31670920 ( click the link to review the publication )

Mol Cancer Ther, 2019, 10.1158/1535-7163.MCT-19-0181

PubMed: 31501278 ( click the link to review the publication )

Cell Prolif, 2019, 52(6):e12680

PubMed: 31454111 ( click the link to review the publication )

Neoplasia, 2019, 22(1):1-9

PubMed: 31751859 ( click the link to review the publication )

Lung Cancer, 2019, 137:85-93

PubMed: 31563735 ( click the link to review the publication )

Cancer Biol Med, 2019, 16(3):606-617

PubMed: 31565489 ( click the link to review the publication )

Artif Cells Nanomed Biotechnol, 2019, 47(1):3231-3238

PubMed: 31373232 ( click the link to review the publication )

DNA Repair (Amst), 2019, 78:37-44

PubMed: 30954901 ( click the link to review the publication )

Front Oncol, 2019, 9:1167

PubMed: 31750252 ( click the link to review the publication )

Cancer Sci, 2019, 110(11):3584-3594

PubMed: 31446643 ( click the link to review the publication )

Biochem Pharmacol, 2019, 169:113640

PubMed: 31536726 ( click the link to review the publication )

Int J Mol Sci, 2019, 20(19)

PubMed: 31546690 ( click the link to review the publication )

J Biol Chem, 2019, 294(12):4488-4497

PubMed: 30679314 ( click the link to review the publication )
Mol Pharmacol, 2019, 95(5):528-536

PubMed: 30858165 ( click the link to review the publication )

Cancer Cell Int, 2019, 19:117

PubMed: 31073278 ( click the link to review the publication )

Mol Carcinog, 2019, 10.1002/mc.23139

PubMed: 31777985 ( click the link to review the publication )

Front Pharmacol, 2019, 10:1116

PubMed: 31649529 ( click the link to review the publication )

Respir Res, 2019, 20(1-:270

PubMed: 31791326 ( click the link to review the publication )

Respir Res, 2019, 20(1):164

PubMed: 31331328 ( click the link to review the publication )

Biomed Pharmacother, 2019, 118:109169

PubMed: 31310954 ( click the link to review the publication )

J Proteomics, 2019, 195:114-124

PubMed: 30660770 ( click the link to review the publication )

Int J Mol Sci, 2019, 20(10)

PubMed: 31121829 ( click the link to review the publication )

Int J Oncol, 2019, 54(2):527-536

PubMed: 30535494 ( click the link to review the publication )

Life Sci, 2019, 224:23-32

PubMed: 30902544 ( click the link to review the publication )

J Drug Target, 2019, 27(4):451-459

PubMed: 30381967 ( click the link to review the publication )

Int J Biochem Cell Biol, 2019, 106:96-106

PubMed: 30471423 ( click the link to review the publication )

Molecules, 2019, 24(3)

PubMed: 30754629 ( click the link to review the publication )

Transl Oncol, 2019, 12(11):1516-1524

PubMed: 31450127 ( click the link to review the publication )

Eur J Pharmacol, 2019, 855:10-19

PubMed: 31028739 ( click the link to review the publication )

Eur J Pharmacol, 2019, 850:97-108

PubMed: 30753867 ( click the link to review the publication )

Eur J Pharmacol, 2019, 856:172409

PubMed: 31132355 ( click the link to review the publication )

Biosci Rep, 2019, 39(8)

PubMed: 31316001 ( click the link to review the publication )

Onco Targets Ther, 2019, 12:6033-6043

PubMed: 31440060 ( click the link to review the publication )

Biomed Res Int, 2019, 2019:3129748

PubMed: 31346515 ( click the link to review the publication )

J Cancer Prev, 2019, 24(4):217-223

PubMed: 31950021 ( click the link to review the publication )

Oncol Lett, 2019, 18(5):5621-5627

PubMed: 31620204 ( click the link to review the publication )

Oncol Lett, 2019, 18(1):368-374

PubMed: 31289508 ( click the link to review the publication )
Anticancer Res, 2019, 39(7):3785-3793

PubMed: 31262905 ( click the link to review the publication )

Exp Ther Med, 2019, 18(5):3793-3800

PubMed: 31611933 ( click the link to review the publication )

Exp Ther Med, 2019, 17(1):953-959

PubMed: 30651886 ( click the link to review the publication )

J Thorac Oncol, 2019, 14(9):1556-1566

PubMed: 31108249 ( click the link to review the publication )

Oncotarget, 2019, 10(11):1171-1192

PubMed: 30838090 ( click the link to review the publication )

Nat Microbiol, 2019, 4(2):216-225

PubMed: 30420785 ( click the link to review the publication )

JCI Insight, 2019, 4(21)

PubMed: 31600169 ( click the link to review the publication )

Oncotarget, 2019, 10(26):2546-2560

PubMed: 31069016 ( click the link to review the publication )

Nat Biomed Eng, 2018, 2(8):578-588

PubMed: 31015631 ( click the link to review the publication )

Nat Biomed Eng, 2018, 2(4):239-253

PubMed: 30936439 ( click the link to review the publication )

Nat Commun, 2018, 9(1):4728

PubMed: 30413706 ( click the link to review the publication )

Nat Commun, 2018, 9(1):2434

PubMed: 29934552 ( click the link to review the publication )

EMBO Mol Med, 2018, 10(3)

PubMed: 29449326 ( click the link to review the publication )

Clin Cancer Res, 2018, 24(13):3097-3107

PubMed: 29506987 ( click the link to review the publication )

Clin Cancer Res, 2018, 24(16):3928-3940

PubMed: 29685880 ( click the link to review the publication )

Theranostics, 2018, 8(5):1256-1269

PubMed: 29507618 ( click the link to review the publication )

J Control Release, 2018, 275:117-128

PubMed: 29474960 ( click the link to review the publication )

J Hematol Oncol, 2018, 11(1):109

PubMed: 30157900 ( click the link to review the publication )

Oncogene, 2018, 37(12):1576-1593

PubMed: 29326440 ( click the link to review the publication )

Cancer Lett, 2018, 424:84-96

PubMed: 29524558 ( click the link to review the publication )

Sci Signal, 2018, 11(549)

PubMed: 30254057 ( click the link to review the publication )

J Exp Clin Cancer Res, 2018, 3;37(1):131

PubMed: 29970127 ( click the link to review the publication )

Cancers (Basel), 2018, 10(6)

PubMed: 29925812 ( click the link to review the publication )

FASEB J, 2018, 10.1096/fj.201800011R

PubMed: 29812969 ( click the link to review the publication )
Exp Mol Med, 2018, 50(1):e435

PubMed: 29371698 ( click the link to review the publication )

Exp Mol Med, 2018, 50(4):52

PubMed: 29700289 ( click the link to review the publication )

Cell Physiol Biochem, 2018, 51(1):337-355

PubMed: 30453282 ( click the link to review the publication )

Cell Commun Signal, 2018, 16(1):77

PubMed: 30409180 ( click the link to review the publication )

Mol Oncol, 2018, 12(2):224-238

PubMed: 29193645 ( click the link to review the publication )

Mol Cell Proteomics, 2018, 17(10):1892-1908

PubMed: 29970458 ( click the link to review the publication )

Eur J Med Chem, 2018, 144:330-348

PubMed: 29275232 ( click the link to review the publication )

Oncogenesis, 2018, 7(9):67

PubMed: 30190455 ( click the link to review the publication )

Mol Cancer Res, 2018, 16(3):543-553

PubMed: 29222171 ( click the link to review the publication )

Mol Cancer Res, 2018, 16(10):1458-1469

PubMed: 29934325 ( click the link to review the publication )

Mol Cancer Res, 2018, 16(11):1773-1784

PubMed: 29967110 ( click the link to review the publication )

Mol Cancer Res, 2018, 16(7):1185-1195

PubMed: 29724813 ( click the link to review the publication )

J Immunol, 2018, 200(8):2809-2818

PubMed: 29531172 ( click the link to review the publication )

Antiviral Res, 2018, 150:20-29

PubMed: 29224735 ( click the link to review the publication )

Biochem Pharmacol, 2018, 152:327-337

PubMed: 29660315 ( click the link to review the publication )

Sci Rep, 2018, 8(1):18043

PubMed: 30575780 ( click the link to review the publication )

J Biol Chem, 2018, 293(35):13401-13414

PubMed: 29997256 ( click the link to review the publication )

Respir Res, 2018, 19(1):96

PubMed: 29784046 ( click the link to review the publication )

Cancer Manag Res, 2018, 10:5785-5798

PubMed: 30510448 ( click the link to review the publication )

Cancer Manag Res, 2018, 10:6695-6703

PubMed: 30584364 ( click the link to review the publication )

Cancer Commun (Lond), 2018, 38(1):50

PubMed: 30053908 ( click the link to review the publication )

Phytomedicine, 2018, 39:33-41

PubMed: 29433681 ( click the link to review the publication )

Int J Oncol, 2018, 52(6):2143-2154

PubMed: 29620166 ( click the link to review the publication )

Invest New Drugs, 2018, 36(6):999-1005

PubMed: 29594878 ( click the link to review the publication )
Cancer Biol Ther, 2018, 19(10):921-933

PubMed: 29856687 ( click the link to review the publication )

Cell Cycle, 2018, 17(23):2577-2592

PubMed: 30488756 ( click the link to review the publication )

Transl Oncol, 2018, 11(6):1406-1418

PubMed: 30219696 ( click the link to review the publication )

Oncol Rep, 2018, 40(4):2171-2182

PubMed: 30106444 ( click the link to review the publication )

Oncol Rep, 2018, 40(4):1937-1946

PubMed: 30106446 ( click the link to review the publication )

Oncol Rep, 2018, 40(2):775-782

PubMed: 29901173 ( click the link to review the publication )

Onco Targets Ther, 2018, 11:8455-8463

PubMed: 30555238 ( click the link to review the publication )

J Ovarian Res, 2018, 11(1):12

PubMed: 29402301 ( click the link to review the publication )

Mol Med Rep, 2018, 18(4):3882-3890

PubMed: 30106133 ( click the link to review the publication )

Oncol Lett, 2018, 15(3):2829-2838

PubMed: 29467862 ( click the link to review the publication )

Oncotarget, 2018, 9(51):29680-29697

PubMed: 30038713 ( click the link to review the publication )

Oncotarget, 2018, 9(26):18254-18268

PubMed: 29719603 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2018, 115(42):E9869-E9878

PubMed: 30275324 ( click the link to review the publication )

Nat Commun, 2017, 8;8:15617

PubMed: 28593995 ( click the link to review the publication )

Nat Commun, 2017, 8(1):410

PubMed: 28871105 ( click the link to review the publication )

Nat Commun, 2017, 1;8(1):1232

PubMed: 29089541 ( click the link to review the publication )

Autophagy, 2017, 13(7):1093-1112

PubMed: 28513279 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2017, 114(15):E3129-E3138

PubMed: 28351972 ( click the link to review the publication )

Genes Dev, 2017, 31(17):1754-1769

PubMed: 28982759 ( click the link to review the publication )

Cancer Res, 2017, 77(13):3551-3563

PubMed: 28428274 ( click the link to review the publication )

Cell Rep, 2017, 21(11):3298-3309

PubMed: 29241554 ( click the link to review the publication )

Mol Cancer, 2017, 16(1):34

PubMed: 28158983 ( click the link to review the publication )

Int J Cancer, 2017, 141(9):1921-1931

PubMed: 28710768 ( click the link to review the publication )

ACS Photonics, 2017, 5(2):487-494

PubMed: 29805987 ( click the link to review the publication )
Oncogene, 2017, 36(8):1102-1111

PubMed: 27524413 ( click the link to review the publication )

Oncogene, 2017, 36(48):6691-6700

PubMed: 28745317 ( click the link to review the publication )

J Med Chem, 2017, 60(17):7447-7458

PubMed: 28787156 ( click the link to review the publication )

Transl Lung Cancer Res, 2017, 6(5):600-610

PubMed: 29114475 ( click the link to review the publication )

Acta Pharmacol Sin, 2017, 38(11):1501-1511

PubMed: 29022575 ( click the link to review the publication )

Oncol Rep, 2017, 38(4):2205-2210

PubMed: 28791365 ( click the link to review the publication )

Eur J Pharmacol, 2017, 821:21-28

PubMed: 29277715 ( click the link to review the publication )

Oncol Rep, 2017, 37(2):1212-1218

PubMed: 27959426 ( click the link to review the publication )

Biochem Biophys Res Commun, 2017, 493(1):213-219

PubMed: 28899783 ( click the link to review the publication )

Biochem Biophys Res Commun, 2017, 482(4):1334-1340

PubMed: 27939888 ( click the link to review the publication )

Biochem Biophys Res Commun, 2017, 486(4):1027-1033

PubMed: 28366635 ( click the link to review the publication )

SLAS Discov, 2017, 22(7):915-922

PubMed: 28346107 ( click the link to review the publication )

Oncol Lett, 2017, 14(4):4349-4354

PubMed: 28959367 ( click the link to review the publication )

Oncotarget, 2017, 8(3):4277-4288

PubMed: 28032592 ( click the link to review the publication )

Oncotarget, 2017, 8(14):22414-22432

PubMed: 26461472 ( click the link to review the publication )

Cell Stem Cell, 2017, 20(2):233-246

PubMed: 27989769 ( click the link to review the publication )

Oncotarget, 2017, 8(70):115620-115631

PubMed: 29383186 ( click the link to review the publication )

Oncotarget, 2017, 8(29):47305-47316

PubMed: 28521301 ( click the link to review the publication )

Oncotarget, 2017, 8(35):58771-58780

PubMed: 28938595 ( click the link to review the publication )

Oncotarget, 2017, 9(2):1641-1655

PubMed: 29416720 ( click the link to review the publication )

Hepatology, 2016, 64(2):488-500

PubMed: 27015352 ( click the link to review the publication )

Genome Biol, 2016, 17:80

PubMed: 27139883 ( click the link to review the publication )

Nat Commun, 2016, 7:11363

PubMed: 27193833 ( click the link to review the publication )

J Clin Invest, 2016, 126(9):3296-312

PubMed: 27482886 ( click the link to review the publication )
Nat Commun, 2016, 7:12231

PubMed: 27456471 ( click the link to review the publication )

Clin Cancer Res, 2016, 22(21):5370-5382

PubMed: 27178741 ( click the link to review the publication )

EMBO Rep, 2016, 17(5):724-38

PubMed: 27013495 ( click the link to review the publication )

J Pathol, 2016, 239(3):320-34

PubMed: 27102572 ( click the link to review the publication )

Acta Neuropathol Commun, 2016, 4(1):96

PubMed: 27586084 ( click the link to review the publication )

Mol Cancer Ther, 2016, 10.1158/1535-7163.MCT-15-0375

PubMed: 27196768 ( click the link to review the publication )

Oral Oncol, 2016, 59:12-19

PubMed: 27424178 ( click the link to review the publication )

Oral Oncol, 2016, 56:62-70

PubMed: 27086488 ( click the link to review the publication )

Biochim Biophys Acta, 2016, 10.1016/j.bbagen.2016.05.011

PubMed: 27180173 ( click the link to review the publication )

Biochim Biophys Acta, 2016, 1859(11):1449-1458

PubMed: 27412911 ( click the link to review the publication )

Sci Rep, 2016, 6:32258

PubMed: 27558531 ( click the link to review the publication )

Clin Lung Cancer, 2016, 17(4):263-270

PubMed: 26707383 ( click the link to review the publication )

J Proteome Res, 2016, 15(12):4490-4504

PubMed: 27794612 ( click the link to review the publication )

Int J Oncol, 2016, 49(4):1427-36

PubMed: 27498706 ( click the link to review the publication )

Int J Oncol, 2016, 48(3):937-44

PubMed: 26783187 ( click the link to review the publication )

Exp Cell Res, 2016, 344(2):194-200

PubMed: 27180268 ( click the link to review the publication )

Eur J Pharmacol, 2016, 789:458-467

PubMed: 27514773 ( click the link to review the publication )

Oncol Rep, 2016, 36(2):729-36

PubMed: 27373987 ( click the link to review the publication )

Neurosurg Focus, 2016, 41(6):E14

PubMed: 27903123 ( click the link to review the publication )

PLoS One, 2016, 11(5):e0155230

PubMed: 27153109 ( click the link to review the publication )

PLoS One, 2016, 11(9):e0163149

PubMed: 27643613 ( click the link to review the publication )

Oncotarget, 2016, 7(4):3847-56

PubMed: 26716903 ( click the link to review the publication )

Oncotarget, 2016, 7(19):27959-74

PubMed: 27058897 ( click the link to review the publication )

Oncotarget, 2016, 7(18-:25983-6002

PubMed: 27036020 ( click the link to review the publication )
Oncotarget, 2016, 7(32):52392-52403

PubMed: 27447558 ( click the link to review the publication )

Cell Res, 2015, 10.1038/cr.2015.16

PubMed: 25656847 ( click the link to review the publication )

Nat Commun, 2015, 6:6377

PubMed: 25758528 ( click the link to review the publication )

Nat Commun, 2015, 6:6240

PubMed: 25670642 ( click the link to review the publication )

J Thorac Oncol, 2015, 10.1097/JTO.0000000000000500

PubMed: 25658629 ( click the link to review the publication )

Clin Cancer Res, 2015, 10.1158/1078-0432.CCR-14-2789

PubMed: 25948633 ( click the link to review the publication )

Clin Cancer Res, 2015, 10.1158/1078-0432.CCR-15-0560

PubMed: 25964297 ( click the link to review the publication )

Proc Natl Acad Sci USA, 2015, 112(6):1839-44

PubMed: 25605917 ( click the link to review the publication )

Cell Rep, 2015, 10.1016/j.celrep.2015.04.049

PubMed: 26027934 ( click the link to review the publication )

Cancer Lett, 2015, 369(1):103-11

PubMed: 26297988 ( click the link to review the publication )

Mol Cancer Ther, 2015, 14(10-:2238-48

PubMed: 26208525 ( click the link to review the publication )

Mol Oncol, 2015, 9(2):527-43

PubMed: 25454348 ( click the link to review the publication )

Mol Cell Proteomics, 2015, 10.1074/mcp.M115.049783 mcp.M115.049783.

PubMed: 25953087 ( click the link to review the publication )

Lung Cancer, 2015, 88(1):16-23

PubMed: 25704955 ( click the link to review the publication )

J Biol Chem, 2015, 290(41):24784-92

PubMed: 26304118 ( click the link to review the publication )

Biochem J, 2015, 465(2):271-9

PubMed: 25351958 ( click the link to review the publication )

J Chromatogr A, 2015, 10.1016/j.chroma.2015.04.055

PubMed: ( click the link to review the publication )

J Chromatogr A, 2015, 1400:117-23

PubMed: 25981288 ( click the link to review the publication )

Toxicol Appl Pharmacol, 2015, 10.1016/j.taap.2015.05.001

PubMed: 25981168 ( click the link to review the publication )

Breast Cancer Res Treat, 2015, 154(2):225-37

PubMed: 26487496 ( click the link to review the publication )

Int J Oncol, 2015, 46(3):1214-24

PubMed: 25530180 ( click the link to review the publication )

Oncol Rep, 2015, 33(4):1860-6

PubMed: 25634113 ( click the link to review the publication )

Oncol Rep, 2015, 34(3):1613-9

PubMed: 26166014 ( click the link to review the publication )

Oncol Rep, 2015, 34(4):1875-82

PubMed: 26238612 ( click the link to review the publication )
PLoS One, 2015, 10(12):e0144368

PubMed: 26656173 ( click the link to review the publication )

Pathol Oncol Res, 2015, 10.1007/s12253-015-9916-9

PubMed: 25749811 ( click the link to review the publication )

Anticancer Res, 2015, 35(5):2795-803

PubMed: 25964559 ( click the link to review the publication )

Int J Radiat Oncol Biol Phys, 2015, 10.1016/j.ijrobp.2015.01.026

PubMed: 25823448 ( click the link to review the publication )

Oncotarget, 2015, 6(7):5118-33

PubMed: 25742786 ( click the link to review the publication )

Oncoscience, 2015, 2(4):419-427

PubMed: 26097875 ( click the link to review the publication )

Oncotarget, 2015, 6(12):10146-60

PubMed: 25760142 ( click the link to review the publication )

Sci Transl Med, 2014, 6(219):219ra9

PubMed: 24431113 ( click the link to review the publication )

Mol Cell, 2014, 55(6):904-15

PubMed: 25219500 ( click the link to review the publication )

Cancer Res, 2014, 74(1):253-62

PubMed: 24165158 ( click the link to review the publication )

Elife, 2014, 3:e02523

PubMed: 24844246 ( click the link to review the publication )

Int J Cancer, 2014, 134(11):2560-71

PubMed: 24374738 ( click the link to review the publication )

Oncogene, 2014, 33(19):2495-503

PubMed: 23728339 ( click the link to review the publication )

Oncogene, 2014, 33(35):4385-95

PubMed: 24096476 ( click the link to review the publication )

MBio, 2014, 5(4):e01340-14

PubMed: 25096879 ( click the link to review the publication )

Cancer Lett, 2014, 342(1):82-91

PubMed: 24001610 ( click the link to review the publication )

Cell Death Dis, 2014, 5:e1445

PubMed: 25299770 ( click the link to review the publication )

Mol Oncol, 2014, 10.1016/j.molonc.2014.05.005

PubMed: 24908424 ( click the link to review the publication )

Mol Oncol, 2014, 9(1):260-9

PubMed: 25226813 ( click the link to review the publication )

Cell Oncol , 2014, 37(5):377-86

PubMed: 25228008 ( click the link to review the publication )

Lung Cancer, 2014, 85(2):141-6

PubMed: 24957682 ( click the link to review the publication )

Antimicrob Agents Chemother, 2014, 10.1128/AAC.02393-14

PubMed: 24663025 ( click the link to review the publication )

Colloids and Surfaces B: Biointerfaces, 2014, 123:61-7

PubMed: 25216919 ( click the link to review the publication )

Drug Metab Dispos, 2014, 42(3):318-22

PubMed: 24335466 ( click the link to review the publication )
Drug Metab Dispos, 2014, 42(11):1851-7

PubMed: 25165131 ( click the link to review the publication )

Int J Oncol, 2014, 45(1):393-400

PubMed: 24819550 ( click the link to review the publication )

Cell Cycle, 2014, 13(24):3808-17

PubMed: ( click the link to review the publication )

Am J Physiol Renal Physiol, 2014, 307(4):F435-44

PubMed: 24990892 ( click the link to review the publication )

Cancer Chemoth Pharm, 2014, 74(3):511-20

PubMed: 25038613 ( click the link to review the publication )

PLoS One, 2014, 9(4):e93651

PubMed: 24695557 ( click the link to review the publication )

PLoS One, 2014, 9(4):e95243

PubMed: 24743578 ( click the link to review the publication )

PLoS One, 2014, 9(12):e114000

PubMed: 25486409 ( click the link to review the publication )

PLoS One, 2014, 9(5):e97719

PubMed: 24874286 ( click the link to review the publication )

Horm Cancer, 2014, 289(24):17195-202

PubMed: 24778185 ( click the link to review the publication )

Exp Mol Pathol, 2014, 97(1):154-165

PubMed: 24984270 ( click the link to review the publication )

Langenbecks Arch Surg, 2014, 10.1007/s00423-014-1235-1

PubMed: 25070024 ( click the link to review the publication )

J BUON, 2014, 19(2):466-73

PubMed: 24965408 ( click the link to review the publication )

Korean J Parasitol, 2014, 52(4):439-41

PubMed: 25246725 ( click the link to review the publication )

Int J Radiat Oncol Biol Phys, 2014, 88(4):947-54

PubMed: 24606853 ( click the link to review the publication )

University of Alberta, 2014, Yahya Muhammad Fiteih

PubMed: ( click the link to review the publication )

Oncotarget, 2014, 5(13):4765-78

PubMed: 24946858 ( click the link to review the publication )

Guangxi Medical University, 2014, Suning Huang

PubMed: ( click the link to review the publication )

JBUON , 2014, 19(2): 466-473

PubMed: ( click the link to review the publication )

Ann Oncol, 2013, 24(2):362-9

PubMed: 22967992 ( click the link to review the publication )

Neuro Oncol, 2013, 15(11):1469-78

PubMed: 24101737 ( click the link to review the publication )

J Clin Endocrinol Metab, 2013, 98(6):2502-12

PubMed: 23559083 ( click the link to review the publication )

Mol Cancer Ther, 2013, 13(2):444-53

PubMed: 24258346 ( click the link to review the publication )

Mol Cancer Ther, 2013, 12(11):2541-58

PubMed: 24026012 ( click the link to review the publication )
Mol Oncol, 2013, 7(1):121-9

PubMed: 23127547 ( click the link to review the publication )

Carcinogenesis, 2013, 34(9):1994-9

PubMed: 23677069 ( click the link to review the publication )

Cell Prolif, 2013, 46(4):447-56

PubMed: 23829318 ( click the link to review the publication )

Radiother Oncol, 2013, 108(3):473-8

PubMed: 23891090 ( click the link to review the publication )

J Biol Chem, 2013, 288(48):34930-42

PubMed: 24142702 ( click the link to review the publication )

Prostate, 2013, 73(13):1453-61

PubMed: 23765757 ( click the link to review the publication )

PLoS One, 2013, 8(12):e81393

PubMed: 24339922 ( click the link to review the publication )

PLoS One, 2013, 8(12):e82625

PubMed: 24349321 ( click the link to review the publication )

Exp Mol Pathol, 2013, 94(2):386-97

PubMed: 23399805 ( click the link to review the publication )

Evid Based Complement Alternat Med, 2013, 2013:243859

PubMed: 23533466 ( click the link to review the publication )

J Genet Syndr Gene Ther, 2013, 4

PubMed: 25520884 ( click the link to review the publication )

Herpesviridae, 2013, 4(1):1

PubMed: 23342981 ( click the link to review the publication )

Oncotarget, 2013, 4(10):1698-1711

PubMed: 24091605 ( click the link to review the publication )

Tuberc Respir Dis, 2013, 75(3):95-103

PubMed: 24101933 ( click the link to review the publication )

Cell Death Differ, 2012, 19(12):1908-16

PubMed: 22722337 ( click the link to review the publication )

Int J Cancer, 2012, 131(12):2961-9

PubMed: 22514082 ( click the link to review the publication )

Int J Cancer, 2012, 131(2):334-43

PubMed: 21858806 ( click the link to review the publication )

Oncogene, 2012, 32(34):4034-42

PubMed: 22964644 ( click the link to review the publication )

Cancer Lett, 2012, 321(2):187-94

PubMed: 22343320 ( click the link to review the publication )

Cancer Sci, 2012, 103(1):7-16

PubMed: 21951556 ( click the link to review the publication )

Biochem Pharmacol, 2012, 84(4):425-31

PubMed: 22634404 ( click the link to review the publication )

Int J Mol Sci, 2012, 13(9):12000-16

PubMed: 23109896 ( click the link to review the publication )

Int J Oncol, 2012, 41(3):869-75

PubMed: 22752005 ( click the link to review the publication )

Cancer Res Treat, 2012, 44(3):202-9

PubMed: 23091447 ( click the link to review the publication )
PLoS One, 2012, 7(9):e42441

PubMed: 22957020 ( click the link to review the publication )

PLoS One, 2012, 7(12):e51549

PubMed: 23272116 ( click the link to review the publication )

Oncotarget, 2012, 2(12):1134-44

PubMed: 22193779 ( click the link to review the publication )

Mol Syst Biol, 2011, 7:486

PubMed: 21525872 ( click the link to review the publication )

Oncogene, 2011, 30(6):737-50

PubMed: 20890302 ( click the link to review the publication )

Antivir Res, 2011, 89(1):64-70

PubMed: 21094187 ( click the link to review the publication )

J Immunother, 2011, 34(4):372-81

PubMed: 21499124 ( click the link to review the publication )

Mol Biosyst, 2011, 7(12):3223-33

PubMed: 21956701 ( click the link to review the publication )

Exp Mol Pathol, 2011, 91(1):400-10

PubMed: 21565184 ( click the link to review the publication )

Vet Comp Oncol, 2011, 11(2):124-39

PubMed: 22235915 ( click the link to review the publication )

Int J Proteomics, 2011, 2011:215496

PubMed: 22091388 ( click the link to review the publication )

Carcinogenesis, 2010, 31(11):1948-55

PubMed: 20837598 ( click the link to review the publication )

Purity & Quality Control

Choose Selective EGFR Inhibitors

Biological Activity

Description

Features

A potent EGFR tyrosine kinase inhibitor.

Targets

Tyr1173 (NR6W cells) ^[1]	Tyr1173 (NR6wtEGFR cells) ^[1]	Tyr992 (NR6wtEGFR cells) ^[1]	Tyr992 (NR6W cells) ^[1]
26 nM	37 nM	37 nM	57 nM

In vitro

Gefitinib effectively inhibits all tyrosine phosphorylation sites on EGFR in both the high and low-EGFR-expressing cell lines including NR6, NR6M and NR6W cell lines. The phosphorylation sites Tyr1173 and Tyr992 are less sensitive requiring higher concentrations of Gefitinib for inhibition. Gefitinib effectively blocks the phosphorylation of PLC-γ, with IC50 of 27nM, in NR6W cells. The NR6wtEGFR and NR6M cell lines has low levels of PLC-γ phosphorylation but the level in the NR6M cell line is more resistant to inhibition by Gefitinib with IC50 of 43 nM and 369 nM, respectively. Gefitinib inhibits Akt phosphorylations, with IC50 of 220 and 263nM, in the low-EGFR- and -EGFRvIII-expressing cell lines, respectively. Gefitinib in the dose range from 0.1 to 0.5μM significantly facilitates, rather than abrogates, colony formation of NR6M cells. However, at a concentration of 2 μM Gefitinib completely blocks NR6M colony formation. Gefitinib rapidly and in a dose-dependent manner inhibits EGFR and ERK phosphorylation up to 72 hours after EGF stimulation in both the high- and low-EGFR-expressing cell lines. ^[1] Gefitinib is the monolayer growth of these EGF-driven untransformed MCF10A cells with an IC50 of 20 nM. ^[2] The combination of Gefitinib (0.2 μM and 0.5 μM) with irradiation lead to a significant growth inhibition in LoVo cells, compared with radiation alone.. ^[3]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
KB	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NH3jeVJKSzVyPUCuNFU1KM7:TR?=	NH;3dHcyPjVzNkS3Ny=>
NIH3T3	NGiz[4JHfW6ldHnvckBCe3OjeR?=	MWCwMlIh\|ryP	M1rQWVIhcA>?	NV\HTItjTE2VTx?=	M4DocGlvcGmkaYTpc44hd2ZiRVfGJJN1cW23bHH0[YQhcHWvYX6g[ZJjSjFiYYX0c5Bpd3OyaH;yfYxifGmxbjD3bZRpKEmFNUCgc4YhOC5yMUS0JO69VQ>?	NVvJWZczOTZ2OECyPFQ>
COS7	MoXXSpVv[3Srb36gRZN{[Xl?	MoLOPVYh\|ryP			NX3Pb2lCUW6qaXLpeIlwdiCxZjDoeY1idiCMQVuyJHY3OTeIIH31eIFvfCCneIDy[ZN{\WR?	Ml61NVcyPzh5MkK=
A549	NHz5[\|JEgXSxdH;4bYMhSXO\|YYm=		NVjNdmpnQTZiaB?=	MX3EUXNQ	M3TKS2lEPTB;MUOuOVkh\|ryP	NGDMPIsyQDNzM{iwOy=>
K562	MWHDfZRwfG:6aXOgRZN{[Xl?		M{nFdlk3KGh?	MXrEUXNQ	MXTJR\|UxRTlwM{[g{txO	NULQelNoOTh\|MUO4NFc>
MDA-MB-231	MV3DfZRwfG:6aXOgRZN{[Xl?		NXXoOY1qQTZiaB?=	MXLEUXNQ	MoX3TWM2OD1\|Nj62NUDPxE1?	MnzvNVg{OTN6MEe=
MOLT4	NFrGbppEgXSxdH;4bYMhSXO\|YYm=		NX3pRldDQTZiaB?=	MWDEUXNQ	NVnvdYpkUUN3ME2xOU4xOiEQvF2=	MnnSNVg{OTN6MEe=
MCF7	NGHNNYZEgXSxdH;4bYMhSXO\|YYm=	M3i2[VUxKM7:TR?=	NEi5Smc4OiCq		MnvyTWM2OD1zMj6wOUDPxE1?	NX[3Ro9wOTh5N{G4NVk>
BT474	M{PUTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MVu3NkBp		M2nHWGFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iQmS0O\|Qh[2WubIOgc5ZmemW6cILld5NqdmdiRWLCZlIhf2m2aDDFR\|UxKG:oIECuN{DPxE1?	NFLa[mIyQTB{OESyOC=>
HN5	NFvaRotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NWfheldrPzJiaB?=		NInMSotCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFjOOUBk\WyuczDveoVz\XiycnXzd4lv\yCHR1\SJJdqfGhiRVO1NEBw\iByLkCxJO69VQ>?	NEn4UIEyQTB{OESyOC=>
BA/F3	NGXPc5VEgXSxdH;4bYMhSXO\|YYm=		MYC3NkBp		NGDpSYxEgXSxdH;4bYNqfHliYXfhbY5{fCCvb4Xz[UBDSS:IMzDj[YxteyCneIDy[ZN{cW6pIFXHSnIhVDh3OGKgcZV1[W62IIfpeIghUUN3MDDv[kAxNjBzMEig{txO	MWSxPVI{QTJ{OR?=
NIH3T3	M3rWPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NYj5T4FxPzJiaB?=		NEK0WXVIem:5dHigbY5pcWKrdHnvckBw\iCvb4Xz[UBPUUhxM2SzJINmdGy\|IHX4dJJme3Orbneg[ZJDOiCpZX7lJJdqfGhiSVO1NEBw\iByLkW0JO69VQ>?	MUKxPVY3PTN5Nx?=
MCF7 MX	NYqxWHYyTnWwY4Tpc44hSXO\|YYm=		M1;kb\|MxKG2rbh?=		MYDJcohq[mm2aX;uJI9nKEKFUmCg[ZhxemW\|c3XkJJdqfGhiSVO1NEBw\iBzLkGg{txO	MnPwNVk6OzJ7NkC=
A431	MnrvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXixNEDPxE1?	MV:3NkBp		NF:0UoNIUTVyPUCuOVE1KM7:TR?=	NEXT[GsyQTl4OUS2OS=>
A431	M3X6VWtqdmG\|ZTDBd5NigQ>?	MUewMlEh\|ryP	MknPNUBp		Mnj5TY5pcWKrdHnvckBw\iCHR1[tbY5lfWOnZDDFS2ZTKHCqb4PwbI9zgWyjdHnvci=>	NXK0eotrOTl7Nkm0OlU>
A431	M4XndGtqdmG\|ZTDBd5NigQ>?	M3T4UFExOCEQvF2=	NW\OZVE1OTBibXnu		Mn\SVJJwdG:wZ3XkJIlvcGmkaYTvdpkh[WO2aY\peJkhd2ZiRVfGMYlv\HWlZXSgSWdHWiCyaH;zdIhwenmuYYTpc44>	NVTlRWxqOTl7Nkm0OlU>
Sf9	M1vOS2tqdmG\|ZTDBd5NigQ>?		M{nNVVExKG2rbh?=	MlfjSG1UVw>?	NFTUblNKdmirYnn0bY9vKG:oIFXHSnIh\XiycnXzd4VlKGG\|c3Xzd4VlKGG\|IHnubIljcXSrb36gc4YhemWlZYD0c5Ih[XW2b4Doc5NxcG:{eXzheIlwdiC5aYToJGlEPTBib3[gNE4xOzNizszN	NVO1VIJ3OjByNU[0NlU>
NCI-H1975	MnG2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVy1JO69VQ>?	MVy3NkBp		MmnqTWM2OD16LkK2JO69VQ>?	M{LxcFIxOTVzNkew
NCI-H1975	MXPLbY5ie2ViQYPzZZk>	NIfyfmEyOCEQvF2=			NUXydohHUW6qaXLpeIlwdiCxZjDFS2ZTKGG3dH;wbI9{eGixconsZZRqd25?	MkniNlAyPTF4N{C=
NCI-H1975	M3TrSmZ2dmO2aX;uJGF{e2G7	Mlq3NVAh\|ryP			M4L2UGlvcGmkaYTpc44hd2ZiRWLCRlIh[XW2b4Doc5NxcG:{eXzheIlwdg>?	Mn3hNlAyPTF4N{C=
NCI-H1975	MmXWSpVv[3Srb36gRZN{[Xl?	NI\GeoY2KM7:TR?=	NW\X[G81PDhiaB?=		MVfJcoR2[3Srb36gc4Yh[XCxcITvd4l{KGG\|c3Xzd4VlKGG\|IHHjeIl3[XSrb36gc4Yh[2G\|cHHz[U0{	MV:yNFE2OTZ5MB?=
A375	NYPlUZMzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MoizOFghcA>?		NXK3[Y9VUUN3ME2yNE42PSEQvF2=	MkTTNlA{ODR3M{e=
SMMC7721	NH3VSnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MYq0PEBp		M2DNNWlEPTB;M{OuNVIh\|ryP	M3r6[\|IxOzB2NUO3
DU145	M4HvTmN6fG:2b4jpZ{BCe3OjeR?=		NYTLb\|RJPSCm	M1PQOWROW09?	NXPwUGJRUUN3ME20Nk4yPyEQvF2=	MX2yNFQ3PjV3NR?=
MIAPaCa2	M17MU2N6fG:2b4jpZ{BCe3OjeR?=		MmnIOUBl	NXTr[5ZzTE2VTx?=	NYixUFd5UUN3ME21NE43OiEQvF2=	NUD2VIRTOjB2Nk[1OVU>
PANC1	NYXTcm06S3m2b4TvfIlkKEG\|c3H5		MYe1JIQ>	MUDEUXNQ	M2rycGlEPTB;NECuOFIh\|ryP	MmPtNlA1PjZ3NUW=
PC9	NIT5RZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1TrVWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgSWdHWi2mZX\pZ4lmdnRiaIXtZY4hWEN7IHPlcIx{KHerdHigSWM2OCCxZjCwMlAyPyEQvF2=	MlXBNlEzODh6MEK=
PC9	M2[yVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3jMSGFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4Sg[5Jwf3SqLYLld4l{fGGwdDDoeY1idiCSQ{mgZ4VtdHNiZYjwdoV{e2mwZzDFS2ZTKEV5NE\fRVc2OC:WN{mwUUBufXSjboSge4l1cCCHQ{WwJI9nKDdizszN	MlzQNlEzODh6MEK=
PC3	M37KbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUCxNEDPxE1?	NXzRSmcxPzJiaB?=	MnP3SG1UVw>?	Ml3uTWM2OD15LkSg{txO	MVuyNVM2OzV2Nh?=
MDA-MB-468	NG\ySIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3PV[\|ExOCEQvF2=	MX:0PEBp	NYDweHdpTE2VTx?=	NIf2fodCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fS=>	Mme5NlE1Ojl4M{K=
Plasmodium falciparum					MUXxTHRUKHC{b3\pcIlv\yCob4KgbY5pcWKrdH;yd{Bw\iCSbHHzcY9lcXWvIH\hcINqeGG{dX2gdJJwdGmoZYLheIlwdg>?	NFvF[YEzOThzN{C0OS=>
NCI-H1993	NFuydmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NYfmVGhLPzJiaB?=	MUnEUXNQ	M{TEXmlEPTB;MD6xJO69VQ>?	M1vqNVIyQTF4NEOz
NCI-H292	M4q3Wmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MkW5O\|IhcA>?	MnfaSG1UVw>?	NI\3NllKSzVyPUCuNFIh\|ryP	MlexNlE6OTZ2M{O=
A431	NXrHOGxCU2mwYYPlJGF{e2G7		MUSyJIg>	M1ixRWROW09?	NIDreYlKdmirYnn0bY9vKG:oIFXHSnIheGixc4Doc5J6dGG2aX;uJIlvKEWJRj3zeIlufWyjdHXkJIh2dWGwIFG0N\|Ehf2m2aDDJR\|UxKG:oIECuNFAyKM7:TR?=	NWLldHZDOjJzMEGxN\|I>
MCF7	Mk\JS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1H6d\|ExOMLizsznM41N	NWqzc\|BOPDhiaB?=	MVvEUXNQ	MWTBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKE2FRkegZ4VtdHNib4\ldoV5eHKnc4PpcochTUeIUjDn[Y5mKHerdHigTWM2OCCxZjCxNk4xPSEQvF2=	MYCyNlEyQTF\|MB?=
BT474	M2TENmN6fG:2b4jpZ{BCe3OjeR?=	NXr4XowxOTBizszN	M1fCb\|Q5KGh?		MWfDfZRwfG:6aXPpeJkh[WejaX7zeEB{\XK3bT3zeIFzfmWmIHj1cYFvKEKWNEe0JINmdGy\|	MUiyNlE{QDNyOB?=
MCF7	MUXDfZRwfG:6aXOgRZN{[Xl?	MmHsNVAh\|ryP	MkDWOFghcA>?		MYDDfZRwfG:6aXPpeJkh[WejaX7zeEB{\XK3bT3zeIFzfmWmIHj1cYFvKE2FRkegZ4VtdHNib4\ldk1mgHC{ZYPzbY5oKEW{YlKyJINmdGy\|	NGXlS5YzOjF\|OEOwPC=>
HCC827	MWfLbY5ie2ViQYPzZZk>	MXWwMlEzPSEQvF2=	M3PzWlI1KGh?	MkjQSG1UVw>?	NIXrcYJKdmirYnn0bY9vKG:oIFXHSnIh\GWuIFW3OFYuSTd3MDDteZRidnRiWUGwOlgh[XW2b4Doc5NxcG:{eXzheIlwdg>?	Mli4NlI{Ozl\|NEK=
HCC827	MoCwT4lv[XOnIFHzd4F6	M3TQe\|AvOTJ3IN88US=>	NY\SO2s{OjRiaB?=	M{HSSGROW09?	M2fEU2lvcGmkaYTpc44hd2ZiRVfGVkBl\WxiRUe0Ok1CPzVyIH31eIFvfC2vZXTpZZRm\CCHcnugdIhwe3Cqb4L5cIF1cW:w	MWiyNlM{QTN2Mh?=
HCC827	NI\0Zo1McW6jc3WgRZN{[Xl?	NFr2RpUxNjF{NTFOwG0>	MmTlNlQhcA>?	M4LDOGROW09?	M2rtRWlvcGmkaYTpc44hd2ZiRVfGVkBl\WxiRUe0Ok1CPzVyIH31eIFvfC2vZXTpZZRm\CCDa4SgdIhwe3Cqb4L5cIF1cW:w	MVGyNlM{QTN2Mh?=
A431	MXfLbY5ie2ViQYPzZZk>	MmT5NVAxKM7:TR?=	MmTMN\|AhdWmw		M{TodGlvcGmkaYTpc44hd2ZiRVfGVkBl\XKrdnXkJIZzd21iaIXtZY4hSTR\|MTDj[YxtKG2nbXLyZY5mKGG\|c3Xzd4VlKGG\|IHnubIljcXSrb36gc4YheG:ueT3HcJUuXHm{IIDoc5NxcG:{eXzheIlwdiC5aYToJGlEPTBib3[gNU4xQCEQvF2=	NH6wbXQzOjZ7OEe4Ni=>
H460	MV;DfZRwfG:6aXOgRZN{[Xl?		NXvNPIRRPzJiaB?=		MUDJR\|UxRTVwNUmg{txO	MoHnNlI4Ojd2NEm=
HT-29	M{\ZSmN6fG:2b4jpZ{BCe3OjeR?=		NGX1RWY4OiCq		M4G4b2lEPTB;Mz6zOkDPxE1?	NEjaRVYzOjd{N{S0PS=>
SGC7901	M3LENGN6fG:2b4jpZ{BCe3OjeR?=		MkS0O\|IhcA>?		NVXLeZFRUUN3ME2xNE4zPiEQvF2=	NUWyWIR{OjJ5Mke0OFk>
A498	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NIfTVZNCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFG0PVgh[2WubIOg[ZhxemW\|c3nu[{BGT0[UIHHu[EBUWkNid3n0bEBKSzVyIH;mJFgvPiEQvF2=	M{TxT\|IzQDF6OES4
Calu3	MWjDfZRwfG:6aXOgRZN{[Xl?	NWDlPVFsOTBizsznM41N	M1vQcFczKGh?		M13DSmlEPTB;MT62JO69VQ>?	MYmyN\|EyPjF4OB?=
FADU	NIP1fmtEgXSxdH;4bYMhSXO\|YYm=	Ml\UNVAh\|rypL33M	M1HUOVczKGh?		M{\QbmlEPTB;MD6wOUDPxE1?	MXeyN\|EyPjF4OB?=
HCC827	MUTDfZRwfG:6aXOgRZN{[Xl?	MX[xNEDPxGdxbVy=	MY[3NkBp		MmfXTWM2OD1yLkCwNVUh\|ryP	NEXZUm8zOzFzNkG2PC=>
PC9	NEjKOYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NX3wUmw2OTBizsznM41N	MlfCO\|IhcA>?		NGf4XINKSzVyPUCuNFE1KM7:TR?=	NHPz[HIzOzFzNkG2PC=>
Sf9	MnLnT4lv[XOnIFHzd4F6		NUjJWI5ZOSCq	M3[yTmROW09?	NHrMOJVKdmirYnn0bY9vKG:oIHj1cYFvKEeVVD30ZYdo\WRiRVfGVkBNQDN2UjDteZRidnRiZYjwdoV{e2WmIIfpeIghUUN3MDDv[kAxNjBzNTFOwG0>	M3fOeVI{PjFzNkmx
16HBE14o-	MkTsR5l1d3SxeHnjJGF{e2G7	MnL6NVAh\|ryP	MlXhO\|IhcA>?	MmnMSG1UVw>?	MW\DfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjCxOmhDTTF2bz2gZ4VtdHNiaHHyZo9zcW6pIIfpcIQhfHmyZTDFS2ZTKGG\|c3Xzd4VlKGG\|IHfyc5d1cCCrbnjpZol1cW:wIIfpeIghUUN3MDDv[kAyOi55MTFOwG0>	MkPWNlM3Pjh2NEG=
NCI-H1975	NWfGWodOS3m2b4TvfIlkKEG\|c3H5	MV:xNEDPxE1?	MkToO\|IhcA>?	MlzqSG1UVw>?	MVjDfZRwfG:6aXPpeJkh[WejaX7zeEBo\W[rdHnubYIuemW\|aYP0ZY51KGi3bXHuJG5EUS2KMUm3OUBk\WyuczDoZZJjd3KrbnegSWdHWiCOOEW4Vk9VPzlyTTDkc5VjdGVibYX0ZY51KGG\|c3Xzd4VlKGG\|IHfyc5d1cCCrbnjpZol1cW:wIIfpeIghUUN3MDDv[kA3NjlzNzFOwG0>	NIDlSJkzOzZ4OES0NS=>
16HBE	Mn\xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MUm3NkBp	MlXtSG1UVw>?	Mn;oRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiBzNljCSUBk\WyuczDlfJBz\XO\|aX7nJJdqdGRidInw[UBGT0[UIIfpeIghUUN3MDDv[kAyNjZyMTFOwG0>	M3nFU\|I{Pzl{M{G4
16HBE	NHrFZ2hHfW6ldHnvckBCe3OjeR?=	MorVNVAxKM7:TR?=	MVmxOVAhdWmw	MWfEUXNQ	MlWwTY5lfWO2aX;uJI9nKG6rdILpZ{BwgGmmZTDwdo9lfWO2aX;uJIlvKGi3bXHuJFE3UEKHIHPlcIx{KGW6cILld5Nqdmdid3ns[EB1gXCnIFXHSnI>	MkPNNlM4QTJ\|MUi=
A549	MoXzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NYXwZWN5PzJiaB?=	MoWxSG1UVw>?	NVvFW4l5SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEB4cWymIIT5dIUhTUeIUj;rMXJieyCmZYDlcoRmdnRiaIXtZY4hSTV2OTDj[YxteyC5aYToJGlEPTBib3[gOE43OjZizszN	MlHjNlM4QTJ\|MUi=
SH-SY5Y	M3e4OmN6fG:2b4jpZ{BCe3OjeR?=		MVS3NkBp		MnjMTWM2OD1zOD6yNUDPxE1?	NH3YN4QzOzh5MUmwPS=>
LoVo	NIj4S3ZMcW6jc3WgRZN{[Xl?		MWqyJEBp	MlPFSG1UVw>?	M2j0dmlvcGmkaYTpc44hd2ZiRVfGVkBxcG:\|cHjvdplt[XSrb36ge4l1cCCLQ{WwJI9nKDBwME[yJO69VQ>?	MkL4NlM6OzB7OUS=
PC9	M4jkbmtqdmG\|ZTDBd5NigQ>?		NXTne4M{OiCq	NXjUcpY5TE2VTx?=	NEDvRo9KdmirYnn0bY9vKG:oIFXHSnIh\XixbjCxPUBl\WyndHnvckBi[3SrdnH0bY5oKG23dHHueEBxcG:\|cHjvdplt[XSrb36gbY4hcHWvYX6gVGM6KGOnbHzzJJdqfGhiSVO1NEBw\iByLkCwPFch\|ryP	NXXn[5FWOjN7M{C5PVQ>
HCC827	M4PIXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NFHacJM4OiCq		MknyTWM2OD1yLkCxNkDPxE1?	M33Hd\|I{QTd\|MU[4
A549	NYrqUWt3U2mwYYPlJGF{e2G7	MlzkNUDPxE1?	NUfRdJRIOSCq	NFXP[m1FVVOR	Mn76TY5pcWKrdHnvckBw\iCHR1\SJIF2fG:yaH;zdIhwenmuYYTpc44hf2m2aDDJR\|UxKG:oIECuNFM6QSEQvF2=	NVLLdWpLOjN7OEizOVQ>
A549	MY\GeY5kfGmxbjDBd5NigQ>?	M1vXN\|Eh\|ryP	NGrScHcyKGh?	NWTydolDTE2VTx?=	NWD3W49ZS2WubIXsZZIhfXC2YXvl	M4DFSVI{QTh6M{W0
HCC827	NHizb2xMcW6jc3WgRZN{[Xl?	M1i1[\|AvPSEQvF2=	MnixNkBp	MkLUSG1UVw>?	M{LWV2lvcGmkaYTpc44hd2ZiRVfGVkBxcG:\|cHjvdplt[XSrb36gbY4h\2WoaYTpcoljNXKnc3nzeIFvfCCqdX3hckBJS0N6MkegZ4VtdHN?	MXKyN\|k6OzN{OB?=
HCC827	NYn2[GF[TnWwY4Tpc44hSXO\|YYm=	Mme2NE42KM7:TR?=	MV[yJIg>	MVLEUXNQ	MnrGTY5pcWKrdHnvckBw\iClLV3leEBxcG:\|cHjvdplt[XSrb36gbY4h\2WoaYTpcoljNXKnc3nzeIFvfCCqdX3hckBJS0N6MkegZ4VtdHN?	MU[yN\|k6OzN{OB?=
HCC827	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUPIRYJYOTBizszN	MlXEO\|IhcA>?	MXPEUXNQ	NW[0NGVSSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBo\W[rdHnubYIue2Wwc3n0bZZmKGi3bXHuJGhESzh{NzDj[YxteyCqYYLic5JqdmdiRVfGVkBGPzR4IITvJGE4PTBiZHXs[ZRqd25id3n0bEBKSzVyIH;mJFAvODB3OEGg{txO	M{T2dlI1ODV\|Nke0
A431	NWDBZok4U2mwYYPlJGF{e2G7	NFfzWIsyODBizszN	M{XJ[VMxKG2rbh?=		M4rke2lvcGmkaYTpc44hd2ZiRVfGVkBqdiC\|aHXkJI1mdWK{YX7lJJZme2mlbHXzJJdqfGhiSVO1NEBw\iBzLkGg{txO	M2LsUVI1ODl2NEOy
BCRP-MDCK2	M1PiSmZ2dmO2aX;uJGF{e2G7	MXWxMlgh\|ryP	MYW3NkBp	NWWzV5kxTE2VTx?=	NITpdHpKdmO{ZXHz[UBw\iCybHHzcYEhdWWvYoLhcoUh\XiycnXzd4lwdiCxZjDCR3JRKGW6cILld5NqdmdicnXwc5J1\XJiZ3Xu[UBITlB?	NH;LWnEzPDF6NEKxNy=>
BCRP-MDCK2	NIKyUXRHfW6ldHnvckBCe3OjeR?=	NFXXSpoyNjhizszN	M3q4e\|czKGh?	MXzEUXNQ	NEWwUJFT\WS3Y4Tpc44hd2ZicHzhd41iKG2nbXLyZY5mKGW6cILld5Nqd25ib3[gRmNTWCCneIDy[ZN{cW6pIILldI9zfGW{IHflcoUhT0[S	NWLtWYJOOjRzOESyNVM>
MDCK	NXnYe\|JKS3m2b4TvfIlkKEG\|c3H5		M4[wOlczKGh?	MoDmSG1UVw>?	NHf2THRIUTVyPUGuOFUh\|ryP	NVzBcXFvOjRzOESyNVM>
MDCK2	M3PzUWZ2dmO2aX;uJGF{e2G7	NILoSXkyNjhizszN	MY[3NkBp	NGfCVXBFVVOR	NFHCdJlKdmirYnn0bY9vKG:oIHj1cYFvKEKFUmCg[ZhxemW\|c3XkJIF{e2W\|c3XkJIF{KEixZXPod5QhOzN\|NEKgZYNkfW23bHH0bY9vKHerdHigTWM2OCCxZjCzMlE6KM7:TR?=	MX:yOFE5PDJzMx?=
A431	MoLDR5l1d3SxeHnjJGF{e2G7		NHvMW444OiCq	NVG1cJM{TE2VTx?=	NXOxdlRCS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hSTR\|MTDj[YxteyCneIDy[ZN{cW6pIFXHSnIhf2m2aDDJR\|UxKG:oIECuOVUh\|ryP	NFvwVFYzPDRzMUGyNy=>
Calu3	NXPyS4pYS3m2b4TvfIlkKEG\|c3H5		MoPWO\|IhcA>?	MXTEUXNQ	MX\DfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDDZYx2OyClZXzsd{BmgHC{ZYPzbY5oKEiHUkKge4l1cCCLQ{WwJI9nKDBwOUmg{txO	NWDZZpZ4OjR2MUGxNlM>
KB	M1j5SWtqdmG\|ZTDBd5NigQ>?	NVzo[GROOTBizszN	NIjqc4YyKGh?	MoDOSG1UVw>?	MkXSTY5pcWKrdHnvckBw\iCHR1[td5RqdXWuYYTl[EBifXSxcHjvd5Bpd3K7bHH0bY9vKG:oIFXHSnIhf2m2aDDJR\|UxKG:oIECuNFI2KM7:TR?=	Ml7ENlQ1OTFzMkO=
BEAS2B	MlXDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFu0PGo2OCEQvF2=	MVe3NkBp	NHiyWlNFVVOR	NHr6PVJKSzVyPUGzMlk1KM7:TR?=	MmLjNlQ3ODd3OUG=
NCI-H1975	Ml[5SpVv[3Srb36gRZN{[Xl?	NHjUb4gyODBizszN	NVqwVYl{OTVyIH3pci=>	M1W1d2ROW09?	MVPJcoR2[3Srb36gc4YhVk9icILv[JVkfGmxbjDpckBpfW2jbjDOR2kuUDF7N{WgZ4VtdHNiaHHyZo9zcW6pIFXHSnIhVDh3OGKvWFc6OE1ibYX0ZY51	NGjORWIzPDZyN{W5NS=>
Hela	M4PpVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MW[yOEBp	NFPrcWJFVVOR	M3\LNWlEPTB;Mj62O{DPxE1?	MkfhNlQ4OzF{OEG=
HepG2	M3\QOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NVzzSVl2OjRiaB?=	NV\pfppzTE2VTx?=	NWfXWJlEUUN3ME22MlQzKM7:TR?=	M4PXNlI1PzNzMkix
Sf9	MkPVT4lv[XOnIFHzd4F6		NIHtPHIyOCCvaX6=	NUHLU2xvTE2VTx?=	MVXJcohq[mm2aX;uJI9nKGG3dH;wbI9{eGixconsZZRqd25ib3[gdoVkd22kaX7hcpQhcGm\|LYTh[4dm\CCHR1\SJEhidWmwbzDhZ4llKDZ2NT2xNVg3MSCneIDy[ZN{\WRid3n0bEBKSzVyIH;mJFAvODJizszN	MorINlQ4OzF{OEG=
SW620	NHPpU3NEgXSxdH;4bYMhSXO\|YYm=		NIHlSok1QCCq	NH3sOIRFVVOR	NHu2WIFKSzVyPUK4MlIh\|ryP	NHfOfGszPDlyMEW5OC=>
HCC827	M{[0U2Z2dmO2aX;uJGF{e2G7	NHz0d5UxNjVizszN	MYqyJIg>	M13uWGROW09?	MVnkc4V{KG6xdDDpcohq[mm2IHOtUYV1KGG\|c3Xzd4VlKGG\|IHnubIljcXSrb36gc4YhSUuWIIDoc5NxcG:{eXzheIlwdg>?	M4HGZlI{QTl\|M{K4
HCC827	NULqTpNITnWwY4Tpc44hSXO\|YYm=	NVmzbWhUOC53IN88US=>	NUPQVlZNOiCq	NWnwdHNNTE2VTx?=	NXTNO2tm\G:nczDuc5QhcW6qaXLpeEBkNU2ndDDhd5Nme3OnZDDhd{BqdmirYnn0bY9vKG:oIIC0OE81OiCyaH;zdIhwenmuYYTpc44>	MWmyN\|k6OzN{OB?=
HCC827	M2HzO2N6fG:2b4jpZ{BCe3OjeR?=	MYqwMlUh\|ryP	M{HOfVczKGh?	MojLSG1UVw>?	NX7JXmE3cGG\|IH7vJIN6fG:2b4jpZ4l1gQ>?	M1vudlI{QTl\|M{K4
NCI-H1975	NEDIOnBHfW6ldHnvckBCe3OjeR?=	NEfnUnkyOCEQvF2=	M3zDNVghcA>?	M37Md2ROW09?	NYXWPGN6\G:nczDuc5QhcW6qaXLpeIkhTUeIUjDhd5Nme3OnZDDhd{Bz\WS3Y4Tpc44hcW5iRWLLJJBpd3OyaH;yfYxifGmxbh?=	MojKNlMyOTZzNki=
A431	NXnyboZkU2mwYYPlJGF{e2G7	MnXDNUDPxE1?	NGna[5AyKGh?	M13qO2ROW09?	M2fGSohieyCwbzDpdpJmfmW{c3nicIUhcW6qaXLpeIlwdiCxZjDFS2ZTKGG3dH;wbI9{eGixconsZZRqd25?	NVfqWmNnOjR7MEC1PVQ>
LNCaP	Mo\zSpVv[3Srb36gRZN{[Xl?	NFrTeIwyOCEQvF2=	NGDke2UzcCCxcjC0JIg>	NVnIZYhxTE2VTx?=	NWjvcIJr\G:nczDuc5QhcW6qaXLpeEBifXSxcHjvd5Bpd3K7bHH0bY9vKG:oIHntcZVvd3C3cnnmbYVlKG[uYXeteIFo\2WmIFLtfEBie3Onc4Pl[EBieyCrbnPvdpBwemG2aX;uJI9nKFt\|MmDdRXRR	MmntNVg3Pjd\|MUK=
H1975	NULxV5pQU2mwYYPlJGF{e2G7	MojINUDPxE1?	M1;I[VI1KGh?	NEnjOlJFVVOR	Mkjk[I9meyCwb4SgbY5pcWKrdDDFS2ZTKHCqb4PwbI9zgWyjdHnvckBqdiCqdX3hckBJOTl5NTDj[YxteyCqYYLic5JqdmdiRVfGVkBNQDV6Uj;UO\|kxVSCvdYThcpQ>	NHexbGszPDZyN{W5NS=>
H1975	NWXTO5R3TnWwY4Tpc44hSXO\|YYm=	MkjJNUDPxE1?	NWn4VWlCOjRiaB?=	M1:yTWROW09?	NIHvcYxld2W\|IH7veEBqdmirYnn0JGVTUyCyaH;zdIhwenmuYYTpc44hcW5iaIXtZY4hUDF7N{WgZ4VtdHNiaHHyZo9zcW6pIFXHSnIhVDh3OGKvWFc6OE1?	MYiyOFYxPzV7MR?=
HCC827	NGjuR2tMcW6jc3WgRZN{[Xl?	NULweIVPOC5zMTFOwG0>	NFrsOoMyKGh?	NVv0[FBITE2VTx?=	MUPoZZMhdm9iaYLy[ZZmenOrYnzlJIlvcGmkaYTpc44hd2ZiRVfGVkBie3Onc4Pl[EBieyC{ZXPveoVzgSCxZjDFS2ZTKGG3dH;wbI9{eGixconsZZRqd25?	NHvPZ40zPDF{NEi5PC=>
H1975	MYLLbY5ie2ViQYPzZZk>	MXqwMlM{KM7:TR?=	NHGyUmQzKGh?	MYfEUXNQ	NUHhXXRU\G:nczDuc5QhcW6qaXLpeEBGT0[UIFy4OVhTN1R5OUDNJIRwfWKuZTDteZRidnRiYYPz[ZN{\WRiYYOgdoVlfWO2aX;uJIlvKEGNVDDwbI9{eGixconsZZRqd25?	NVnnclZWOjRzMkS4PVg>
H1975	MXvLbY5ie2ViQYPzZZk>	NUHTbm1EOC5\|MzFOwG0>	NHfGd4IzKGh?	M{OwVWROW09?	NYLkTVIx\G:nczDuc5QhcW6qaXLpeEBGT0[UIFy4OVhTN1R5OUDNJIRwfWKuZTDteZRidnRiYYPz[ZN{\WRiYYOgdoVlfWO2aX;uJIlvKEWUSzDwbI9{eGixconsZZRqd25?	NUfYO5Y5OjRzMkS4PVg>
H1975	M4XZO2tqdmG\|ZTDBd5NigQ>?	MVewMlM{KM7:TR?=	MkXGNkBp	MXjEUXNQ	NW[2TFgx\G:nczDuc5QhcW6qaXLpeEBGT0[UIFy4OVhTN1R5OUDNJIRwfWKuZTDteZRidnRicHjvd5Bpd3K7bHH0bY9v	MUCyOFEzPDh7OB?=
H1975	M37DVGtqdmG\|ZTDBd5NigQ>?	NV;NeVQ4OC5zMkWg{txO	NUj6fXc2OjRiaB?=	MXrEUXNQ	MV;kc4V{KG6xdDDpcohq[mm2IFXHSnIhVDh3OGKvWFc6OE1ibYX0ZY51KFlzME[4JIF2fG:yaH;zdIhwenmuYYTpc44>	NFG1cHYzOjN\|OUO0Ni=>
H1975	NWrTNY96U2mwYYPlJGF{e2G7	MmG4NE42KM7:TR?=	NFnLe4YzPCCq	NUPpc3ZFTE2VTx?=	NXPZeHJ6\G:nczDuc5QhcW6qaXLpeEBGT0[UIFy4OVhTN1R5OUDNJI12fGGwdD3t[YRq[XSnZDDFdosheGixc4Doc5J6dGG2aX;u	NXnYR5Y2OjJ\|M{mzOFI>
H1975	MUHLbY5ie2ViQYPzZZk>	MXewMlUh\|ryP	MUKyOEBp	M4jn[GROW09?	NYHPR241\G:nczDuc5QhcW6qaXLpeEBGT0[UIFy4OVhTN1R5OUDNJI12fGGwdD3t[YRq[XSnZDDBb5QheGixc4Doc5J6dGG2aX;u	M{TXSVIzOzN7M{Sy
MIAPaCa2	Mn62S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmXPNk42KM7:TR?=	MkHLO\|IhcA>?	NYfBZ2k6TE2VTx?=	NX;tdYlucGG\|IH7vJIdzd3e2aDDpcohq[mm2aX;u	NWHNW451OjB2Nk[1OVU>
MIAPaCa2	M2nFVWN6fG:2b4jpZ{BCe3OjeR?=	MWqxJO69VQ>?	NW\5d2VlOTBiZB?=	M2ri[GROW09?	M{XQSohieyCwbzDjfZRwfG:6aXPpeJkh[XO\|ZYPz[YQh[XNic4XwdJJme3Orb36gc4Yh[2:ub375JIZwem2jdHnvci=>	NH;qNpUzODR4NkW1OS=>
MIAPaCa2	NELrTFhCeG:ydH;zbZMhSXO\|YYm=	MXqxNEDPxE1?	MU[yOIghd3JiNEigbC=>	MXjEUXNQ	M3PDeYRw\XNibn;0JIlv\HWlZTDhdI9xfG:\|aYO=	M4TsUFIxPDZ4NUW1
MIAPaCa2	NH\DT4dCeG:ydH;zbZMhSXO\|YYm=	MUSyNEDPxE1?	M2C0[FI1KGh?	MnLJSG1UVw>?	M3nWbYRw\XNibn;0JIlv\HWlZTDhdI9xfG:\|aYOgZZN{\XO\|ZXSgZZMh[2G\|cHHz[UA{KGGldHn2ZZRqd25?	M4fLeFIxPDZ4NUW1
EoL-1	MoHLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVPJR\|UxRTVwMUegcm0>	NITRZYZUSU6JRWK=
NCI-H720	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVnJR\|UxRTJ4LkmyJI5O	M1\qenNCVkeHUh?=
NCI-SNU-5	NVfLXlJ7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NF;p[lZKSzVyPUK4MlE6KG6P	M3z0R3NCVkeHUh?=
EW-3	Ml30S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{WxXWlEPTB;NE[uNFQhdk1?	NUTpfZlYW0GQR1XS
HCC2218	MoW4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1TiOWlEPTB;NUCuOVkhdk1?	MVnTRW5ITVJ?
HuO-3N1	MoT4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUH0fVFuUUN3ME21Ok4xQSCwTR?=	Mn;5V2FPT0WU
DB	MlTDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVnJR\|UxRTZyLkm2JI5O	NHT4PWhUSU6JRWK=
HSC-4	MojVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYnyO\|gyUUN3ME22NU42OyCwTR?=	NX;peG9rW0GQR1XS
DOK	M3\hcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVviU5BoUUN3ME25N{43OiCwTR?=	M4X2b3NCVkeHUh?=
H9	MmTxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NW\2b3pHUUN3ME2xN\|cvOiCwTR?=	NEXBS2JUSU6JRWK=
NCI-H292	M{jjTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NITvS3BKSzVyPUG2Nk43PiCwTR?=	MXLTRW5ITVJ?
HSC-2	NYKyVWdqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M33GR2lEPTB;MU[1MlU4KG6P	NGPpTXZUSU6JRWK=
LU-65	Mlr4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MkjoTWM2OD1zNk[uOlEhdk1?	MWHTRW5ITVJ?
BV-173	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3yxdGlEPTB;MUi2MlU2KG6P	MnHGV2FPT0WU
LB2241-RCC	NVe5PWlnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MX7JR\|UxRTF7ND65N{BvVQ>?	M{S3Z3NCVkeHUh?=
KG-1	M3fBcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1zCbWlEPTB;MkC0MlM1KG6P	NYDzeFE3W0GQR1XS
CHL-1	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFvM[mxKSzVyPUKwPE42OSCwTR?=	MnHsV2FPT0WU
KYSE-140	NXLobHhKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnHzTWM2OD1{MEmuPVYhdk1?	MoK2V2FPT0WU
DU-145	NXPiRldtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnrOTWM2OD1{MUmuNFQhdk1?	M1\2SnNCVkeHUh?=
EW-13	NW[xPIFGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGPMNJlKSzVyPUKyOU4yKG6P	NFjhR25USU6JRWK=
KYSE-450	NHfpT2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NETs[XBKSzVyPUK0O{46OiCwTR?=	M364d3NCVkeHUh?=
CAL-72	NGfte2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUPJR\|UxRTJ4OD63N{BvVQ>?	MmTvV2FPT0WU
MEG-01	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1rD[2lEPTB;Mke2Mlc3KG6P	MYrTRW5ITVJ?
HCE-T	NWj4eWZMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MoH6TWM2OD1{N{muO\|khdk1?	MnnUV2FPT0WU
NCI-SNU-1	Moe5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NV;0ZmlZUUN3ME2yPFMvOzJibl2=	NGW4dZlUSU6JRWK=
CAL-27	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWXZZ2JuUUN3ME2yPFkvODhibl2=	NVfXOlVbW0GQR1XS
BALL-1	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlzjTWM2OD1{OUeuOFIhdk1?	NFzRc5lUSU6JRWK=
SBC-1	M3rmNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGW4bINKSzVyPUOwO{44QSCwTR?=	MYjTRW5ITVJ?
CAL-54	M{DEWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXrw[5NMUUN3ME2zNVEvOjNibl2=	NUnKdpdyW0GQR1XS
TI-73	MlXXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWDJR\|UxRTNzMj63OUBvVQ>?	NEK1PXlUSU6JRWK=
P12-ICHIKAWA	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXjJR\|UxRTN{OD6wOkBvVQ>?	MYXTRW5ITVJ?
ACHN	MlfNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlvXTWM2OD1\|M{GuOEBvVQ>?	NHPyTIxUSU6JRWK=
PC-14	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NELETolKSzVyPUOzN{41OSCwTR?=	M4m4fHNCVkeHUh?=
HCC1806	M37V[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MoLKTWM2OD1\|M{euOVEhdk1?	M1rxenNCVkeHUh?=
SK-MEL-24	MmfaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYKyfVdYUUN3ME2zN\|cvQDdibl2=	NI[wTY9USU6JRWK=
A4-Fuk	M365[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NX\6TYlkUUN3ME2zOVAvODJibl2=	NYLyU5hOW0GQR1XS
ECC10	M4fM[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2jnO2lEPTB;M{WyMlk3KG6P	MnLLV2FPT0WU
KASUMI-1	NHfnemxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mk[1TWM2OD1\|Nk[uO\|Mhdk1?	NF7JZnFUSU6JRWK=
CAL-33	M1HZbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUPqbIxNUUN3ME2zO\|AvQSCwTR?=	MVLTRW5ITVJ?
MDA-MB-175-VII	MmfyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NX7NUVU5UUN3ME2zO\|gvQDhibl2=	M1G3NHNCVkeHUh?=
NUGC-3	MoCwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MY\JR\|UxRTRyMT64NUBvVQ>?	M2rQS3NCVkeHUh?=
KY821	NIDYc4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{Pjc2lEPTB;NEC4MlU4KG6P	NGPZZ29USU6JRWK=
CTB-1	NUWzSHJHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mnj6TWM2OD12MkSuOEBvVQ>?	NEm0OWZUSU6JRWK=
DoTc2-4510	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFzOSHJKSzVyPUS0Nk4yOiCwTR?=	M1vae3NCVkeHUh?=
EFO-27	NH[yT3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MoDqTWM2OD12NUSuO\|Qhdk1?	M2HJb3NCVkeHUh?=
BPH-1	M4S4Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmDhTWM2OD12OUGuNVYhdk1?	MnzEV2FPT0WU
KYSE-270	MmHDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYLJR\|UxRTR7OD62OUBvVQ>?	NInBSnJUSU6JRWK=
HO-1-N-1	M2LFbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVLNblU6UUN3ME21NFkvOjVibl2=	M3f6OHNCVkeHUh?=
SK-MEL-1	NWjRRoM{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{TYS2lEPTB;NUGwMlk6KG6P	NWnoenpRW0GQR1XS
MOLT-13	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NF3ReI5KSzVyPUWxOE45OiCwTR?=	MYXTRW5ITVJ?
TK10	Mlf3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXXJR\|UxRTVzNT6xNUBvVQ>?	NYXHbFRZW0GQR1XS
HN	NF3BNoFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M13QUGlEPTB;NUG3MlM5KG6P	MV;TRW5ITVJ?
SCC-15	NXPJXId5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWrJR\|UxRTV{NT62PEBvVQ>?	M124[3NCVkeHUh?=
NCI-H358	MmfxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{LWRWlEPTB;NUK3MlY3KG6P	MkK4V2FPT0WU
KYSE-180	NVPXNlBiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NEDhOZBKSzVyPUWzNE43OiCwTR?=	MUDTRW5ITVJ?
NCI-H82	NXvPVWdpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWnJR\|UxRTV2MD61JI5O	NV[yTHNtW0GQR1XS
NB7	M3HoUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mlr6TWM2OD13NE[uN\|Ihdk1?	NHPibIRUSU6JRWK=
DSH1	M2qyN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHXCfVFKSzVyPUW2Ok45QCCwTR?=	MUXTRW5ITVJ?
RS4-11	NXziSGtuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYL4eldZUUN3ME21OlgvPTlibl2=	NVrke3NiW0GQR1XS
CAN	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1r0S2lEPTB;NUiwMlc3KG6P	NVvHR21wW0GQR1XS
Ca9-22	NH;se5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWDJR\|UxRTV6OD62OEBvVQ>?	M3zxS3NCVkeHUh?=
CAL-39	NH7Z[IxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHXYOIxKSzVyPUW5Ok4{KG6P	Mn3MV2FPT0WU
NCI-H1623	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnyzTWM2OD13OUmuN\|Yhdk1?	MlvXV2FPT0WU
FADU	MnixS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NIfOW4FKSzVyPU[wOE43QSCwTR?=	MXHTRW5ITVJ?
NB69	NIf2eVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mm\FTWM2OD14MUSuN\|Uhdk1?	MoDJV2FPT0WU
Ramos-2G6-4C10	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MkntTWM2OD14MkGuOFYhdk1?	M{m3NXNCVkeHUh?=
LB1047-RCC	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmTDTWM2OD14MkWuNlkhdk1?	NH7XO\|BUSU6JRWK=
MV-4-11	NXz2U2hxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mn\KTWM2OD14MkeuO{BvVQ>?	NVvpOmRtW0GQR1XS
DBTRG-05MG	NXLEWGsxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlzzTWM2OD14M{KuNlghdk1?	NVzuW2Q4W0GQR1XS
ME-180	MoXVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NITDWmdKSzVyPU[zNk46KG6P	MYnTRW5ITVJ?
NBsusSR	NV31cFdUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1fwOmlEPTB;NkS2MlUzKG6P	NFS4OHpUSU6JRWK=
COR-L105	MnPNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MkHRTWM2OD14NkKuOVMhdk1?	NYnHUG92W0GQR1XS
ETK-1	M3PjVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWHIcHhQUUN3ME22OlIvPTlibl2=	NIPmS2lUSU6JRWK=
L-363	NXTRWWNxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NIXvOo5KSzVyPU[3NU46PCCwTR?=	MXLTRW5ITVJ?
LU-134-A	NEf0XoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mn[1TWM2OD15MUmuNFkhdk1?	NWHUV4N3W0GQR1XS
NCI-H1770	NUXObnR7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnHXTWM2OD15MkKuOEBvVQ>?	NYP5eW5yW0GQR1XS
HAL-01	NXi4OW53T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MoP0TWM2OD15M{SuO\|Ehdk1?	NGqyfWpUSU6JRWK=
COLO-684	NWj5SmlPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHvBdppKSzVyPUe1N{4xOSCwTR?=	M2O5XnNCVkeHUh?=
TE-6	NYnDUmJ[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWTkfIJZUUN3ME23OlQvOzFibl2=	MlXPV2FPT0WU
A431	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVHoT3lQUUN3ME23PFAvODRibl2=	NILuPWxUSU6JRWK=
LU-135	NHnPdW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWTJR\|UxRTd6Mz6wN{BvVQ>?	M{eydHNCVkeHUh?=
EC-GI-10	NFTzcoJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYLJR\|UxRTd6OD61NkBvVQ>?	M2Tr[HNCVkeHUh?=
TE-12	NHz1PZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXvMd3ZXUUN3ME24NlEvOTFibl2=	NH7BR\|FUSU6JRWK=
LoVo	M1S3UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWXQPVVXUUN3ME24OVkvODZibl2=	NYn4XVFyW0GQR1XS
23132-87	NXnnfIlCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MX;JR\|UxRTh4ND6yPEBvVQ>?	M3u5ZnNCVkeHUh?=
AU565	MoXVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2\i[mlEPTB;OE[5MlYhdk1?	MlvSV2FPT0WU
DEL	M4TTeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MoPPTWM2OD16N{euOlUhdk1?	MmH6V2FPT0WU
COR-L88	NVfTU3VIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGfPNpNKSzVyPUi4Nk4zPiCwTR?=	MVzTRW5ITVJ?
NCI-H2126	NWjweFZ2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYPJR\|UxRTh6Mj64N{BvVQ>?	NHXHVmpUSU6JRWK=
CAPAN-1	NEHSTJNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1\OW2lEPTB;OEizMlI6KG6P	MWHTRW5ITVJ?
BT-474	M{LiPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlXzTWM2OD17M{iuNVQhdk1?	MU\TRW5ITVJ?
BHY	NHmxNIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYjTWmFKUUN3ME25O\|UvPDhibl2=	NFjVSXhUSU6JRWK=
HT-3	NUTKVmVMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MUjJR\|UxRTl6Mj60NUBvVQ>?	MUfTRW5ITVJ?
SK-NEP-1	M1rMTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2fSbWlEPTB;OUi5MlQ1KG6P	MU\TRW5ITVJ?
MS-1	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2\PT2lEPTB;OUm0MlY6KG6P	MUHTRW5ITVJ?
DOHH-2	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4fDZmlEPTB;MT6wNFAzOSEQvF2=	M4G2TXNCVkeHUh?=
NCI-H1304	Moe0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MkXuTWM2OD1zLkCxOlQ{KM7:TR?=	MW\TRW5ITVJ?
EM-2	MonYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3\hS2lEPTB;MT6wN\|AyPiEQvF2=	NITYZ2RUSU6JRWK=
MHH-PREB-1	M4TKRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Ml;ETWM2OD1zLkC4OFUyKM7:TR?=	NVLVfWNiW0GQR1XS
KU-19-19	MojwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYfJcXVQUUN3ME2xMlA5PTRzIN88US=>	MWPTRW5ITVJ?
NCI-H1648	M3nibGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYP6R29IUUN3ME2xMlExPjF4IN88US=>	MX7TRW5ITVJ?
MKN1	M3ruPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGLreHVKSzVyPUGuNlE6QDdizszN	NEPnUGFUSU6JRWK=
SNU-449	NIDvRWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1;BPGlEPTB;MT6yNlIxQCEQvF2=	MXnTRW5ITVJ?
OAW-42	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnzjTWM2OD1zLkK3PFI2KM7:TR?=	NH\V[3hUSU6JRWK=
769-P	M4jBfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MoXDTWM2OD1zLkK3PVE5KM7:TR?=	NYDITIpiW0GQR1XS
SW1088	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGHsNFBKSzVyPUGuNlk3ODdizszN	MW\TRW5ITVJ?
GCIY	NIi4NJNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYn3cYwyUUN3ME2xMlMxOTN{IN88US=>	M2\NRXNCVkeHUh?=
CTV-1	NH3wVVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmrXTWM2OD1zLkOwPEDPxE1?	NFy2VllUSU6JRWK=
NCI-H1092	MlrlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NF2yRnZKSzVyPUGuN\|A5PSEQvF2=	MUnTRW5ITVJ?
NKM-1	NVHBSVRVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXXJR\|UxRTFwM{K1PVch\|ryP	NXK0OYZnW0GQR1XS
NCI-H1650	MkHMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUDJR\|UxRTFwM{O0PFIh\|ryP	MlryV2FPT0WU
SW954	M4jRcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NV3WXHNlUUN3ME2xMlM1ODR6IN88US=>	NHzKfGNUSU6JRWK=
SW48	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVHJR\|UxRTFwM{[2NVgh\|ryP	MXrTRW5ITVJ?
SK-N-DZ	M2\pZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{TkR2lEPTB;MT6zOlk1PyEQvF2=	M1j2[nNCVkeHUh?=
KMOE-2	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2nHWmlEPTB;MT6zPVgyPSEQvF2=	MYHTRW5ITVJ?
NB5	M2DuU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4fhZmlEPTB;MT60NFg6PCEQvF2=	MY\TRW5ITVJ?
CCRF-CEM	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWC2Z2pCUUN3ME2xMlQyOTFizszN	NI\aVHlUSU6JRWK=
RH-1	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVPJR\|UxRTFwNEGxN\|Yh\|ryP	NXPBSZJuW0GQR1XS
NCI-H526	NWP3T2Q5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3vQS2lEPTB;MT60N\|gzPiEQvF2=	NG\Kbm5USU6JRWK=
697	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NF\peoJKSzVyPUGuOFQyODRizszN	M{jQeXNCVkeHUh?=
J82	MlX2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVyxXXZlUUN3ME2xMlQ2PzZ4IN88US=>	MYPTRW5ITVJ?
BE-13	NXXROG9NT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4\OWWlEPTB;MT61NFY4OSEQvF2=	M{jwWnNCVkeHUh?=
SAS	NGLpbGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MV7JR\|UxRTFwNUG2NlIh\|ryP	M3;CfHNCVkeHUh?=
SCC-25	NYrPUnJFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXzSOppzUUN3ME2xMlUzOzJ{IN88US=>	NXXvbHUxW0GQR1XS
LAMA-84	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHPaTJNKSzVyPUGuOVM5OTVizszN	MWXTRW5ITVJ?
HSC-3	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHHyVppKSzVyPUGuOVQ{QCEQvF2=	MmXCV2FPT0WU
BT-549	M3PEV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MoHuTWM2OD1zLkW4O\|Q4KM7:TR?=	NIqySGxUSU6JRWK=
ML-2	NVv5VItUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYPJR\|UxRTFwNkSwNlkh\|ryP	NGDlWINUSU6JRWK=
BB30-HNC	NXXpUFBNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mn\ZTWM2OD1zLk[4PVczKM7:TR?=	M2S0NHNCVkeHUh?=
PANC-03-27	MlzGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1j1PWlEPTB;MT63NFE{QSEQvF2=	MVPTRW5ITVJ?
COLO-678	MmP5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1PaeGlEPTB;MT63N\|Q1PCEQvF2=	MUDTRW5ITVJ?
NCI-H1666	NVK3O2U5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUPifJN3UUN3ME2xMlc1PzB2IN88US=>	MYnTRW5ITVJ?
NCI-H209	NXjrT4VDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmDtTWM2OD1zLke3NlY6KM7:TR?=	MXLTRW5ITVJ?
EPLC-272H	NUfqdop{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlTqTWM2OD1zLki1OVQ6KM7:TR?=	M3jMdHNCVkeHUh?=
OMC-1	M{\IUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2nYeWlEPTB;MT65PVg5QCEQvF2=	M3HUdHNCVkeHUh?=
HCC70	M4Lwemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHq2N25KSzVyPUKuNFA5OTVizszN	NWjxR\|dzW0GQR1XS
CAL-12T	M37WRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MU\JR\|UxRTJwMEG4OlEh\|ryP	MmnGV2FPT0WU
TGBC24TKB	NETu[3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1;qVGlEPTB;Mj6wNlk3OSEQvF2=	NEL3e3pUSU6JRWK=
EKVX	M4q1cGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4fhU2lEPTB;Mj6wOFk{QSEQvF2=	MV3TRW5ITVJ?
SW1116	MkG0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWm5PZNCUUN3ME2yMlA3ODB7IN88US=>	MV3TRW5ITVJ?
NCI-H2009	NVi3O5VGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXjRfW1MUUN3ME2yMlA3OjF2IN88US=>	NHjJbpVUSU6JRWK=
RPMI-8866	NXT0dZI4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGfIcpdKSzVyPUKuNFg1QDFizszN	M4DXUXNCVkeHUh?=
KARPAS-45	NWTxcIZXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYrKfnZiUUN3ME2yMlEzPDd7IN88US=>	NWfr[Hg4W0GQR1XS
RXF393	MkPrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFjVN4xKSzVyPUKuNVMxOzZizszN	MXjTRW5ITVJ?
786-0	NFracZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUSy[2Y{UUN3ME2yMlE5PDB4IN88US=>	NWH2cnZHW0GQR1XS
SCC-4	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWDBRW42UUN3ME2yMlIyPzd4IN88US=>	MX;TRW5ITVJ?
BT-20	NWfES2dHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXfWN\|RUUUN3ME2yMlI3PzR2IN88US=>	MlrEV2FPT0WU
A498	NIHkPIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUTVT5RRUUN3ME2yMlI6PDF3IN88US=>	NWH2e48{W0GQR1XS
IGROV-1	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXfKUml[UUN3ME2yMlMyOjN5IN88US=>	MXXTRW5ITVJ?
JVM-3	NI\VcZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGjQb\|VKSzVyPUKuN\|Q3PDNizszN	M{LPN3NCVkeHUh?=
NCI-H2170	M3rpW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NETSS3hKSzVyPUKuN\|Q4QDNizszN	NFO4ZYJUSU6JRWK=
EW-18	NGrXVY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1LPSGlEPTB;Mj6zOVQ4OSEQvF2=	NXPtT2wzW0GQR1XS
KU812	NXrNdIJZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NIPsUW5KSzVyPUKuN\|Y4PzlizszN	Mm\EV2FPT0WU
NY	M3vjbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NEPSUXpKSzVyPUKuN\|czPyEQvF2=	MVvTRW5ITVJ?
HTC-C3	M4XPSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYDXcpN[UUN3ME2yMlQzOjZ5IN88US=>	Ml;lV2FPT0WU
CFPAC-1	M4D6dWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NITwXnpKSzVyPUKuOFM5PjRizszN	MWDTRW5ITVJ?
HH	NH;jTpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mlr6TWM2OD1{LkS5PFU1KM7:TR?=	MYnTRW5ITVJ?
MKN7	M360eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3LTNWlEPTB;Mj62Nlc1QCEQvF2=	M12yUHNCVkeHUh?=
TE-8	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1[4fmlEPTB;Mj62N\|Y2OyEQvF2=	MkDwV2FPT0WU
MC-IXC	M{TaWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1OyVGlEPTB;Mj62OFQ2OyEQvF2=	NHHRVJNUSU6JRWK=
DMS-79	MmXtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NH:zbXRKSzVyPUKuOlkzQDRizszN	M2e5OnNCVkeHUh?=
Detroit562	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUDZXFlJUUN3ME2yMlY6QDR3IN88US=>	M4XDOXNCVkeHUh?=
HuP-T4	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3LoOmlEPTB;Mj63NlgyQCEQvF2=	NWG2V5AxW0GQR1XS
QIMR-WIL	NFfhU4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYnZc3ZFUUN3ME2yMlc2QTV{IN88US=>	Mn:0V2FPT0WU
BB65-RCC	NVrUdXRZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlXDTWM2OD1{LkiwO\|E{KM7:TR?=	MmLQV2FPT0WU
PC-3	MoC2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHO3dpZKSzVyPUKuPFM{OTdizszN	NXLF[npzW0GQR1XS
OVCAR-3	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVvJR\|UxRTJwOEW1PVQh\|ryP	M33CO3NCVkeHUh?=
KYSE-510	NUXyTZh2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWPJR\|UxRTJwOE[3PFYh\|ryP	NGW5NIxUSU6JRWK=
HC-1	MkjaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4jtfmlEPTB;Mj65OFAyOiEQvF2=	NITYeGVUSU6JRWK=
NCI-H1693	MoTqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MV;JR\|UxRTJwOUW4PVch\|ryP	M3LWZ3NCVkeHUh?=
DU-4475	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3K1VmlEPTB;Mj65PVA2OiEQvF2=	MoPtV2FPT0WU
COLO-680N	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVf5VmgyUUN3ME2zMlAxPDl3IN88US=>	NUDaeYFDW0GQR1XS
MN-60	M2\EWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGXFdnFKSzVyPUOuNFQ6PzRizszN	M3nje3NCVkeHUh?=
BCPAP	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4jBd2lEPTB;Mz6wPFI6PSEQvF2=	NXWwbppjW0GQR1XS
647-V	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYHJR\|UxRTNwMU[yNkDPxE1?	M2XPXnNCVkeHUh?=
HT-1376	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXr2bVdnUUN3ME2zMlIxPTB4IN88US=>	NYm4WI9pW0GQR1XS
NCI-H1793	M2Ptd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHP6RZFKSzVyPUOuNlExQThizszN	NUjQSHdsW0GQR1XS
SW1463	NGHHd25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWLJR\|UxRTNwMk[xPVIh\|ryP	M3XDSXNCVkeHUh?=
NCI-H727	NHT1N4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUHhW3NRUUN3ME2zMlM5PTh2IN88US=>	MoTIV2FPT0WU
LB771-HNC	M1jPb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1f2OWlEPTB;Mz6zPVEzPiEQvF2=	NXnZO2FyW0GQR1XS
D-542MG	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUPJR\|UxRTNwNESyNlIh\|ryP	NG\4T5ZUSU6JRWK=
NTERA-S-cl-D1	MonFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVS2R2xiUUN3ME2zMlQ1QTV5IN88US=>	M2O1cXNCVkeHUh?=
C8166	NV\kRpNmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYnEV2h1UUN3ME2zMlQ3PTJzIN88US=>	NYjPXpZJW0GQR1XS
639-V	M1izfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NV\ZN3J{UUN3ME2zMlU4Pzl{IN88US=>	MVHTRW5ITVJ?
TE-1	NGf0WlZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnPRTWM2OD1\|LkW5NVY6KM7:TR?=	M4T4OnNCVkeHUh?=
OAW-28	NVXzOnk1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWjBNYFbUUN3ME2zMlU6PDJ4IN88US=>	MlnDV2FPT0WU
SK-LU-1	MmP4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3exWWlEPTB;Mz62NFY1PSEQvF2=	NXu0W\|hwW0GQR1XS
CaR-1	MnHUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MkLMTWM2OD1\|Lk[xNFQ5KM7:TR?=	MYLTRW5ITVJ?
A2780	Ml3nS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXPLXIZCUUN3ME2zMlY1ODh7IN88US=>	M4\W[3NCVkeHUh?=
C2BBe1	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGDIfXdKSzVyPUOuOlQ1ODdizszN	MULTRW5ITVJ?
SK-MES-1	Mly2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYfWNGxyUUN3ME2zMlY1PjF2IN88US=>	NGDFSnJUSU6JRWK=
PANC-10-05	NWXvd3RFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGL5OW5KSzVyPUOuO\|IxPzJizszN	Mm\TV2FPT0WU
J-RT3-T3-5	NGmwWGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVfJR\|UxRTNwN{W0NFYh\|ryP	NGTtXJhUSU6JRWK=
ES4	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXiyTVJRUUN3ME2zMlgzOjh4IN88US=>	NXnETlkzW0GQR1XS
NCI-H28	NFfjSIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmTITWM2OD1\|LkiyPVYyKM7:TR?=	NF3ZWYFUSU6JRWK=
NCI-H1155	MlXKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MV\JR\|UxRTNwOESxOVkh\|ryP	MXfTRW5ITVJ?
KURAMOCHI	NWO1cIFCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Ml7MTWM2OD1\|Lki2NFU3KM7:TR?=	MWjTRW5ITVJ?
NCI-H69	M3P4dWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGTkV5hKSzVyPUOuPVAyPzhizszN	NFy3PIFUSU6JRWK=
IST-MES1	NWiwe3Y2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mk\3TWM2OD1\|Lkm0NFI6KM7:TR?=	MmnpV2FPT0WU
NH-12	NUG1NJp1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWH3TpZYUUN3ME2zMlk1OTh5IN88US=>	NFG0RllUSU6JRWK=
JVM-2	MoqwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MljmTWM2OD1\|Lkm0O\|UzKM7:TR?=	MW\TRW5ITVJ?
EW-16	NEPWOZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mn;JTWM2OD1\|Lkm1OVc4KM7:TR?=	NHHDR5dUSU6JRWK=
NCI-H441	NGDN[INIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWTNTpJZUUN3ME2zMlk4ODF2IN88US=>	NGfTfnhUSU6JRWK=
RCC10RGB	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NV3HRVV[UUN3ME20MlAyOjR4IN88US=>	NXrWVIFXW0GQR1XS
TCCSUP	NFniT3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmnJTWM2OD12LkGxNFUh\|ryP	NGLLWZFUSU6JRWK=
HL-60	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MX\JR\|UxRTRwMUKyOFEh\|ryP	M2S3UHNCVkeHUh?=
EW-11	M{HkSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MoG5TWM2OD12LkGzNlYyKM7:TR?=	M3HWbHNCVkeHUh?=
KARPAS-299	M{e0[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mon6TWM2OD12LkOxNFE{KM7:TR?=	M4P0bXNCVkeHUh?=
SNU-C2B	NUjy[HlOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4GzdGlEPTB;ND6zOFY5PiEQvF2=	M4G1PHNCVkeHUh?=
LU-139	NVLJVGIyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVfzTGVPUUN3ME20MlM4OjR5IN88US=>	MoTLV2FPT0WU
HCC1937	NVPRXm9JT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2DSZ2lEPTB;ND6zO\|k6OyEQvF2=	NGLwbYpUSU6JRWK=
GR-ST	M1Kyemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1zwfWlEPTB;ND60N\|E5KM7:TR?=	M1S0enNCVkeHUh?=
SK-OV-3	M2Lw[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWHWb25tUUN3ME20MlQ3ODR{IN88US=>	MWrTRW5ITVJ?
A172	MknKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUTJR\|UxRTRwNUW1NlEh\|ryP	M2KzTnNCVkeHUh?=
NB10	NGT4emVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFT3NJJKSzVyPUSuOVk4QDFizszN	M2e4RXNCVkeHUh?=
P30-OHK	M4XVfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MojKTWM2OD12LkixPVI6KM7:TR?=	NHyxfJdUSU6JRWK=
KYSE-520	NVr2bWtDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3Hsb2lEPTB;ND64PFAyQCEQvF2=	MYLTRW5ITVJ?
KNS-62	NFTsenpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NH;GcoJKSzVyPUSuPVA5ODdizszN	NYnPfJpIW0GQR1XS
ES1	Mk\2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NX24e3pXUUN3ME20Mlk3ODN3IN88US=>	M2PJeXNCVkeHUh?=
KOSC-2	NWTxPWplT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGfCfXNKSzVyPUSuPVk6PTlizszN	NY\MbotTW0GQR1XS
TE-9	M3XYeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlzxTWM2OD13LkCxOVI2KM7:TR?=	MojnV2FPT0WU
NCI-H1838	NXvOSnJPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1LyZWlEPTB;NT6wNlA4PiEQvF2=	MkG1V2FPT0WU
KP-N-YN	NFrVPXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHrxRY9KSzVyPUWuNVI2QTFizszN	MY\TRW5ITVJ?
ALL-PO	NHjKV4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1fWbGlEPTB;NT6yNlU5PyEQvF2=	M1PRZnNCVkeHUh?=
NOMO-1	NYTJfGxTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGLqeIpKSzVyPUWuNlMyPzZizszN	M4XYUnNCVkeHUh?=
CGTH-W-1	NY\tWYtET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MonyTWM2OD13LkO4OVg1KM7:TR?=	M4mzXXNCVkeHUh?=
ATN-1	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFjTe\|lKSzVyPUWuOFEyQDRizszN	NFO5[pFUSU6JRWK=
AGS	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NIm3TnNKSzVyPUWuOFk3OThizszN	M1GwXnNCVkeHUh?=
SW13	MlvYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NIPXelhKSzVyPUWuOVMzPjVizszN	M1PXVHNCVkeHUh?=
SW1990	MnvGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NIPl[5BKSzVyPUWuOlIzQDVizszN	M2XJbHNCVkeHUh?=
BFTC-905	M4HH[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MX3JR\|UxRTVwNkW4O\|gh\|ryP	M2\v[3NCVkeHUh?=
RMG-I	Mo\QS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFizXHRKSzVyPUWuOlU6PDJizszN	NIL0N4lUSU6JRWK=
HD-MY-Z	NEHCeZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIjwbnlKSzVyPUWuOlg2QDFizszN	MneyV2FPT0WU
HCC1187	NVPhT252T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXXJR\|UxRTVwN{GwN\|Ih\|ryP	NFjB[5BUSU6JRWK=
HCC2998	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MkfoTWM2OD13LkexPFc4KM7:TR?=	M2rpcXNCVkeHUh?=
RT-112	NWDpbFR3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NF;YfGhKSzVyPUWuPVAzPDVizszN	MmT0V2FPT0WU
CAKI-1	NX\zTnF[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MUTJR\|UxRTZwMEC5PFUh\|ryP	NYTxNWxxW0GQR1XS
HDLM-2	NFLRT2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{XFTmlEPTB;Nj6wNVQ5QSEQvF2=	NV7YWWpPW0GQR1XS
TE-10	NHHiNFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHTjcphKSzVyPU[uNFQ5OzNizszN	MmjzV2FPT0WU
KE-37	NGHHfFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mnu2TWM2OD14LkC3NlU5KM7:TR?=	MnXoV2FPT0WU
RCM-1	NGTNSGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MV;JR\|UxRTZwMEe3NVkh\|ryP	MX\TRW5ITVJ?
Mewo	NFfxVXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Moi4TWM2OD14LkGxOFg4KM7:TR?=	NF2xXXhUSU6JRWK=
L-428	NX7kXGprT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MULJR\|UxRTZwMUiwN\|ch\|ryP	NXPTTJZsW0GQR1XS
8-MG-BA	M3HqUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4DyTmlEPTB;Nj6xPVM4QSEQvF2=	NXvPVYJiW0GQR1XS
SK-MEL-28	NWCzOY05T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NEi4[3VKSzVyPU[uNlA6PjdizszN	MYrTRW5ITVJ?
VA-ES-BJ	Mn2xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{nsT2lEPTB;Nj6zNFQ3OiEQvF2=	MnLjV2FPT0WU
CAL-120	NUTOfmpMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYrESoNLUUN3ME22MlQ2OTZ{IN88US=>	NUfwU\|VkW0GQR1XS
GAMG	M3fJc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1TvUGlEPTB;Nj61NFYzKM7:TR?=	MlHZV2FPT0WU
MSTO-221H	NFjxd\|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2ruc2lEPTB;Nj61NVE4KM7:TR?=	MkfDV2FPT0WU
GCT	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Ml;PTWM2OD14LkWzN\|g4KM7:TR?=	NXn5N5hTW0GQR1XS
SH-4	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MV\JR\|UxRTZwNUi4OFQh\|ryP	MYTTRW5ITVJ?
Calu-3	NXXTbHN4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NEnrUllKSzVyPU[uOlU2PjhizszN	MmjHV2FPT0WU
SK-HEP-1	M4\FOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUi0[WZnUUN3ME22MlcyPzV\|IN88US=>	MWrTRW5ITVJ?
PFSK-1	NFrQZm1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWXjUoVuUUN3ME22Mlc{PDd6IN88US=>	NF7PbZdUSU6JRWK=
NB12	NYP5XVFVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlW4TWM2OD14Lke4OFA1KM7:TR?=	MXLTRW5ITVJ?
A388	M{DtXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGHB[GNKSzVyPU[uPFk2OiEQvF2=	M3f0R3NCVkeHUh?=
KLE	MkOzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWm1blRIUUN3ME22Mlk3PTF4IN88US=>	MmnGV2FPT0WU
TE-11	MljES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYr2[WFjUUN3ME23MlA1QTZ5IN88US=>	MWjTRW5ITVJ?
NCI-H2405	Ml22S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlG1TWM2OD15LkC4N\|k{KM7:TR?=	MXfTRW5ITVJ?
OVCAR-4	M{DVR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mmj3TWM2OD15LkG1N\|Uh\|ryP	MUfTRW5ITVJ?
KP-N-YS	M17MeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWezNWRFUUN3ME23MlE5OTRizszN	M2HFRnNCVkeHUh?=
NOS-1	Mn\PS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2XYUWlEPTB;Nz6yOVgzQCEQvF2=	NEjM[XpUSU6JRWK=
DMS-114	NGrvepZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXyySnU2UUN3ME23MlI6PjNzIN88US=>	NWDJ[FV1W0GQR1XS
NCI-H2030	M1jt[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVTJR\|UxRTdwM{O2PVgh\|ryP	M{nwXHNCVkeHUh?=
HEL	NHu5TJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmTITWM2OD15LkO3OVIyKM7:TR?=	NY\ZR2ZDW0GQR1XS
CAL-62	M4DJSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXjVfoZ2UUN3ME23MlM6QDZ4IN88US=>	NUfoOGhSW0GQR1XS
COLO-668	NX3ZS5g4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4DCSmlEPTB;Nz60N\|k3PyEQvF2=	NI\QNFNUSU6JRWK=
SKG-IIIa	NInNcW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnW4TWM2OD15LkS1N\|gyKM7:TR?=	MXTTRW5ITVJ?
HCC1419	Ml;WS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{XnUmlEPTB;Nz60Olg{OyEQvF2=	NHzzRm1USU6JRWK=
OS-RC-2	Mlv5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NIi5NHJKSzVyPUeuOFk5QTRizszN	NVLQXHExW0GQR1XS
COLO-829	MmfiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXzJR\|UxRTdwNk[0OlMh\|ryP	M33iTXNCVkeHUh?=
NB13	MkXqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYLzUZhDUUN3ME23MlgzPjZ5IN88US=>	Ml\yV2FPT0WU
DK-MG	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MljXTWM2OD15LkizNlAyKM7:TR?=	MWnTRW5ITVJ?
SHP-77	MoLlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlK3TWM2OD15Lki2OlU{KM7:TR?=	NHz5PJNUSU6JRWK=
NCI-H661	NFPwNG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4nDdmlEPTB;OD6wOVg3PyEQvF2=	MnG3V2FPT0WU
AM-38	NIrncnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Ml[wTWM2OD16LkG2Nlgh\|ryP	MmjiV2FPT0WU
VM-CUB-1	M3PJU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXHJR\|UxRThwMUewNlkh\|ryP	MUXTRW5ITVJ?
KYSE-70	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NX;GepU6UUN3ME24MlE6PzZzIN88US=>	NVnQOI04W0GQR1XS
5637	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1XMbGlEPTB;OD6zNVA2PSEQvF2=	NEHjc\|BUSU6JRWK=
TGBC11TKB	NH\QTWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2H3WmlEPTB;OD60OlE3PCEQvF2=	M4DvOXNCVkeHUh?=
EGI-1	NFrsS4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUXJR\|UxRThwNkCwPFgh\|ryP	NWD3N2NNW0GQR1XS
D-392MG	M1nhNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWLjSZZiUUN3ME24MlY3OjF2IN88US=>	MoD4V2FPT0WU
A673	NWLkcI16T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4PBVGlEPTB;OD62O\|YyOSEQvF2=	MoTQV2FPT0WU
COLO-792	NHjpSHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGO3OoNKSzVyPUiuO\|Q6PDZizszN	Mn7tV2FPT0WU
NCI-H1792	NXHSeIFYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MX7JR\|UxRThwOEi5NFMh\|ryP	M1vTSHNCVkeHUh?=
LS-1034	MnHiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUPkPZRZUUN3ME24Mlk1PjV{IN88US=>	NYLNSI1GW0GQR1XS
D-566MG	NIHTO4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXj4S\|dNUUN3ME25MlAyQDFizszN	M1f2W3NCVkeHUh?=
NCI-H226	NF7JSW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mn;DTWM2OD17LkC5JO69VQ>?	NX;yVpR7W0GQR1XS
ChaGo-K-1	NV62b29JT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MkTZTWM2OD17LkGwOVc6KM7:TR?=	MYPTRW5ITVJ?
NCI-H2228	NGmxfZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NV\MTJlDUUN3ME25MlEyODhzIN88US=>	M1PCbXNCVkeHUh?=
RPMI-8226	Mn6zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYfKRXZRUUN3ME25MlEyOzB2IN88US=>	M{nFeXNCVkeHUh?=
BFTC-909	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXjJR\|UxRTlwMUiyPVch\|ryP	NGTKTlRUSU6JRWK=
HPAF-II	NYTCV\|dIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWXJR\|UxRTlwMkK1NVgh\|ryP	NXr4dmkxW0GQR1XS
Capan-2	MkXtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4eyRWlEPTB;OT60NFExQSEQvF2=	M{\GOXNCVkeHUh?=
IA-LM	M2fvXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NW\YU3A3UUN3ME25MlQyQTZ4IN88US=>	NHXtSI9USU6JRWK=
KP-4	NWCyWFJmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4e2XmlEPTB;OT60PFg{QCEQvF2=	MYTTRW5ITVJ?
A101D	M1;1PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWrJR\|UxRTlwNUG3NVkh\|ryP	NHy2[YtUSU6JRWK=
EFO-21	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MkDWTWM2OD17LkW4O\|M2KM7:TR?=	MY\TRW5ITVJ?
C32	M1LSPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MU\JR\|UxRTlwNkOzOEDPxE1?	NX7MUXJ3W0GQR1XS
SW837	NIXmW4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1zrcWlEPTB;OT64OFgzKM7:TR?=	M2focnNCVkeHUh?=
OCI-AML2	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2j1S2lEPTB;OT64Olk3KM7:TR?=	NHe3SItUSU6JRWK=
NCI-H1355	M2K4[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXrkUVFHUUN3ME25Mlk1ODh6IN88US=>	NVPNXWpWW0GQR1XS
NCI-H2342	M2\PbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1XMcWlEPTB;MUCuNFE2PSEQvF2=	MVPTRW5ITVJ?
A204	NFrvUJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVT4U3RXUUN3ME2xNE4xPDZ4IN88US=>	NGrBO4lUSU6JRWK=
CAL-51	M4GxUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWX2Oot7UUN3ME2xNE4xQDd5IN88US=>	M3;OS3NCVkeHUh?=
HCE-4	NF3jT3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXzJR\|UxRTFyLkGxNlIh\|ryP	NEDMTW5USU6JRWK=
NCI-H810	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWLJR\|UxRTFyLkG1PVch\|ryP	NWTMOGRoW0GQR1XS
DJM-1	NI[ze3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MkWxTWM2OD1zMD6xO\|MzKM7:TR?=	NEn1O3NUSU6JRWK=
SK-UT-1	MlP0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHjhbWJKSzVyPUGwMlI2PzRizszN	M1;vVXNCVkeHUh?=
U031	NUjWWnlkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHfLOGlKSzVyPUGwMlI3QDZizszN	MnvJV2FPT0WU
YH-13	Mmm5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXHEVldvUUN3ME2xNE4{ODV5IN88US=>	MY\TRW5ITVJ?
K5	M4jGSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Ml7YTWM2OD1zMD6zN\|k2KM7:TR?=	MmnLV2FPT0WU
HEC-1	NU\Te293T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3r1UGlEPTB;MUCuOFA5OSEQvF2=	NXLhb5Y4W0GQR1XS
A2058	NXq1[3VwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1WxZmlEPTB;MUCuOVQ6OSEQvF2=	NGKwWphUSU6JRWK=
SW962	NX3mcZZiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4jYdmlEPTB;MUCuOlIxPCEQvF2=	Mk[0V2FPT0WU
VMRC-RCZ	MoLsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2[w[GlEPTB;MUCuOlc1QSEQvF2=	MoXJV2FPT0WU
D-336MG	MmHXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1;0UWlEPTB;MUCuO\|AxPSEQvF2=	NU[xdmVWW0GQR1XS
LXF-289	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2XRZ2lEPTB;MUCuO\|k3PyEQvF2=	NFjqZXpUSU6JRWK=
SW900	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MX;JR\|UxRTFyLkiyNlgh\|ryP	MULTRW5ITVJ?
K-562	M4T2NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4f4U2lEPTB;MUCuPFM6PSEQvF2=	M{naXnNCVkeHUh?=
HCC38	NXHUSVQ3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHnHepRKSzVyPUGwMlk4OTZizszN	NWe1epBrW0GQR1XS
SF-295	NIHKbnBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVHJR\|UxRTFyLkm5NFIh\|ryP	NH7WdFVUSU6JRWK=
LB831-BLC	M{fJe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXm2W2JJUUN3ME2xNU4zPTV4IN88US=>	MXLTRW5ITVJ?
FTC-133	NEPTeJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MW\JR\|UxRTFzLkOwPFEh\|ryP	MlX1V2FPT0WU
HCC1954	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MV;JR\|UxRTFzLkSzOkDPxE1?	NYfqZ45wW0GQR1XS
GOTO	NGWyemZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NH7YbY1KSzVyPUGxMlUzODZizszN	M3jiWXNCVkeHUh?=
LS-411N	MnPUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXrSR2dOUUN3ME2xNU43OTBzIN88US=>	MmK0V2FPT0WU
RPMI-7951	M4LMfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYK3N5BoUUN3ME2xNU43OzR6IN88US=>	MX7TRW5ITVJ?
NCI-H1299	NVjTeJZTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXXJR\|UxRTFzLk[2OFch\|ryP	MnLnV2FPT0WU
MLMA	M1y3XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVnhPVZxUUN3ME2xNU43QTl5IN88US=>	MV;TRW5ITVJ?
MMAC-SF	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYmxSopEUUN3ME2xNU44OjV{IN88US=>	NHnlfG1USU6JRWK=
UM-UC-3	NH\yRlBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVnJR\|UxRTFzLke0NlEh\|ryP	MWPTRW5ITVJ?
SCC-9	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWizSo1xUUN3ME2xNU45OTVzIN88US=>	NIPKRWdUSU6JRWK=
HOS	NWLhNY55T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MUnJR\|UxRTFzLki2PFMh\|ryP	NXrV[5YyW0GQR1XS
OE19	MlTMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NEfQOXNKSzVyPUGxMlk{PjdizszN	MXjTRW5ITVJ?
Mo-T	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mn3uTWM2OD1zMT65OVQyKM7:TR?=	MYPTRW5ITVJ?
CAMA-1	NWXGNHkzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NEjDbIlKSzVyPUGyMlE3OzNizszN	M3q2OnNCVkeHUh?=
U-118-MG	MmnUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnLZTWM2OD1zMj6yOFQyKM7:TR?=	M2rJd3NCVkeHUh?=
KS-1	MmHRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mkm2TWM2OD1zMj6yPFMzKM7:TR?=	MkLOV2FPT0WU
JAR	NULmXYF2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NIi5c5BKSzVyPUGyMlM{PjlizszN	MXPTRW5ITVJ?
ABC-1	NGjDTmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mo\kTWM2OD1zMj6zOFEh\|ryP	MUPTRW5ITVJ?
Daoy	NUHZbm9kT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MV7JR\|UxRTF{LkS1OFIh\|ryP	NHLUNldUSU6JRWK=
C3A	NWfjUYx3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1fPbWlEPTB;MUKuOVc5PSEQvF2=	M1:5b3NCVkeHUh?=
GT3TKB	MmrVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXm4dlREUUN3ME2xNk43OzJ5IN88US=>	MkHmV2FPT0WU
DMS-273	Mn\BS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXnJR\|UxRTF{Lki2N\|Mh\|ryP	NV3QeoN3W0GQR1XS
G-361	NISx[FBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXvJR\|UxRTF{LkmxNlkh\|ryP	MlzhV2FPT0WU
RH-18	NX:5UWFGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3S1UGlEPTB;MUOuNlk3OiEQvF2=	NEHDfVhUSU6JRWK=
SN12C	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFe4PGdKSzVyPUGzMlM5ODhizszN	NUXNfZFCW0GQR1XS
NCI-H1993	MlfkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3\3dWlEPTB;MUOuOFI5PSEQvF2=	M1\5TXNCVkeHUh?=
LOXIMVI	NILQXXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2\GRmlEPTB;MUOuOlE2OSEQvF2=	MX;TRW5ITVJ?
SK-PN-DW	NEfyOIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIj2PWxKSzVyPUGzMlg1OjdizszN	M3G3VnNCVkeHUh?=
KALS-1	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUPJR\|UxRTF\|Lki1NlUh\|ryP	NEjvfmtUSU6JRWK=
LAN-6	NF;HbYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4X6TWlEPTB;MUSuNlU{KM7:TR?=	MnfmV2FPT0WU
A549	MoXNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVfBeXVkUUN3ME2xOE41PzF{IN88US=>	NUmzN\|F[W0GQR1XS
RD	M{XaZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2Lab2lEPTB;MUSuOFgyOyEQvF2=	MX\TRW5ITVJ?
TGBC1TKB	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYj4d\|dkUUN3ME2xOE43PjF3IN88US=>	NULkVFZQW0GQR1XS
NCI-H630	NG\PVoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWLJR\|UxRTF2Lkm0Olch\|ryP	NIL2U2xUSU6JRWK=
MIA-PaCa-2	NFXndIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{DFSmlEPTB;MUSuPVY6KM7:TR?=	M1\QeXNCVkeHUh?=
NCI-H1755	M37jSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXTaWJJUUUN3ME2xOE46QTV\|IN88US=>	M3uwc3NCVkeHUh?=
MOLT-4	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmDTTWM2OD1zNT6wOFk4KM7:TR?=	NVPtN5ZTW0GQR1XS
CW-2	MoTZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFW2eGVKSzVyPUG1MlE1OjFizszN	Mnz0V2FPT0WU
COLO-320-HSR	NUTmdI4xT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MW\JR\|UxRTF3LkWzNFch\|ryP	MkfSV2FPT0WU
UMC-11	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1\O[GlEPTB;MUWuO\|UzOyEQvF2=	M4W3[HNCVkeHUh?=
MCF7	NF72SolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWPJR\|UxRTF3LkixOFUh\|ryP	Mn3hV2FPT0WU
NCI-H23	MoTMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmDNTWM2OD1zNT64OFM5KM7:TR?=	MXjTRW5ITVJ?
HuCCT1	NXi0fWRtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MV\JR\|UxRTF3Lki3OEDPxE1?	NWHYUZl3W0GQR1XS
MPP-89	MnLJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MkPoTWM2OD1zNT65OFE4KM7:TR?=	NYH5fnh1W0GQR1XS
HT55	Mnj6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mmr6TWM2OD1zNT65OFc5KM7:TR?=	NYTXPXVYW0GQR1XS
no-11	NUDzOIJwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlTtTWM2OD1zNT65OlY{KM7:TR?=	NEG4UJlUSU6JRWK=
GP5d	NUO2bGs{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXnqe4ZiUUN3ME2xOk4zOTh5IN88US=>	M{DjbnNCVkeHUh?=
BHT-101	M3rENGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NV\yR\|ZGUUN3ME2xOk4zPDN7IN88US=>	MXzTRW5ITVJ?
M059J	NX;abHM5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MUnJR\|UxRTF4LkK4OEDPxE1?	M1HaenNCVkeHUh?=
D-283MED	NWrNT2ROT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHXmfJpKSzVyPUG2MlQzODlizszN	NW\v[Jk6W0GQR1XS
BEN	Mlz1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4CyR2lEPTB;MU[uOVE2PSEQvF2=	NGDXdIRUSU6JRWK=
LB373-MEL-D	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFTpXmxKSzVyPUG2MlczOzJizszN	M3nSNHNCVkeHUh?=
MEL-HO	MoXDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWjpVnpqUUN3ME2xOk45QDV2IN88US=>	NHPpVYZUSU6JRWK=
GI-ME-N	NUi2NZFXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mn;WTWM2OD1zNj65NFMzKM7:TR?=	M3HnSXNCVkeHUh?=
RKO	NHvqd3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWnTXmxkUUN3ME2xO{4xPzR6IN88US=>	MUPTRW5ITVJ?
MZ2-MEL	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXu4WodyUUN3ME2xO{4yOzNizszN	MlTJV2FPT0WU
NCI-H1573	M4jVNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NE\XfnJKSzVyPUG3MlI5OjZizszN	NYPpTIpnW0GQR1XS
NCI-H1581	MofvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnzBTWM2OD1zNz60OFEyKM7:TR?=	NYPSbmttW0GQR1XS
NCI-H747	NF30NG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{HVZ2lEPTB;MUeuOVI6PyEQvF2=	NHryXWJUSU6JRWK=
SW1783	MmCxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmrDTWM2OD1zNz62OFE2KM7:TR?=	NFTzU3VUSU6JRWK=
Calu-6	MnroS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M37qRmlEPTB;MUeuOlc5OiEQvF2=	MUXTRW5ITVJ?
SF268	NF\ydmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2rzU2lEPTB;MUeuOlk3QSEQvF2=	NGDwSllUSU6JRWK=
ES8	NXfrTVB[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWr6[Fl1UUN3ME2xO{45PTl\|IN88US=>	M1jMbnNCVkeHUh?=
KM-H2	NXrlZVJST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlLNTWM2OD1zNz65OFEyKM7:TR?=	M{SyRnNCVkeHUh?=
D-502MG	NWPyV3dpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NIDtfFRKSzVyPUG3Mlk5ODhizszN	M4PjNXNCVkeHUh?=
HLE	Mm\yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnjBTWM2OD1zOD6zNVQ5KM7:TR?=	NGn3NphUSU6JRWK=
SW982	M2XiN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MV3JR\|UxRTF6LkSwO\|Uh\|ryP	Mo\yV2FPT0WU
MDA-MB-361	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NETR[49KSzVyPUG4MlU2QDhizszN	NUPH[otsW0GQR1XS
NCI-H1563	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mn:4TWM2OD1zOD63NVI1KM7:TR?=	NILoem9USU6JRWK=
MFE-280	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MkK5TWM2OD1zOD63Nlk{KM7:TR?=	NYTYUZRCW0GQR1XS
U251	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NEPBb3lKSzVyPUG4Mlc{PDdizszN	NYrOOlQ2W0GQR1XS
KNS-42	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mkf0TWM2OD1zOD64NFE2KM7:TR?=	NUHDXlRxW0GQR1XS
U-266	NHixZlJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlnuTWM2OD1zOD64OlQ6KM7:TR?=	NV\abWNlW0GQR1XS
OVCAR-8	NWrTTFhGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MkD2TWM2OD1zOD65Nlc3KM7:TR?=	NEf0Nm9USU6JRWK=
MFH-ino	NUS4OIl6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYrFe\|BHUUN3ME2xPE46PjZ7IN88US=>	NWfVRXNvW0GQR1XS
D-263MG	Ml\MS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVTJR\|UxRTF7LkCxO\|Ih\|ryP	NHfoe\|JUSU6JRWK=
NCI-H1437	NVniOpRyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFvyZmlKSzVyPUG5MlA1PjdizszN	NXSzU2hGW0GQR1XS
NCI-H1048	NELON3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWHJR\|UxRTF7LkKzNlYh\|ryP	MX7TRW5ITVJ?
NCI-H446	Mly3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHiy[2FKSzVyPUG5MlM2QDlizszN	NIDG[3NUSU6JRWK=
NCI-N87	M{Hlbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3TJUmlEPTB;MUmuOVk6OiEQvF2=	NXnhdoVQW0GQR1XS
WM-115	NXj0bWl3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXHGcZZlUUN3ME2xPU43Pzd2IN88US=>	NYHv[ox3W0GQR1XS
HuH-7	M4eweWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MkXJTWM2OD1zOT63OFIyKM7:TR?=	NH6weo1USU6JRWK=
NCI-H650	MoDPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mli0TWM2OD1zOT63OVA5KM7:TR?=	MmXvV2FPT0WU
TYK-nu	M1jrSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXXJR\|UxRTF7LkizO\|gh\|ryP	MWDTRW5ITVJ?
Becker	NV;DSZZwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2\0UmlEPTB;MUmuPFU1PyEQvF2=	MV\TRW5ITVJ?
BB49-HNC	M{PPcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXrJR\|UxRTF7LkmyJO69VQ>?	Mn;SV2FPT0WU
HGC-27	M4jzZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUn0fGp5UUN3ME2yNE4yOzl2IN88US=>	NXzyZ3VRW0GQR1XS
SiHa	M4flNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWXQOoU5UUN3ME2yNE4{PzF{IN88US=>	NXnoNYd3W0GQR1XS
LB2518-MEL	NYmyeolzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYPVcHB{UUN3ME2yNE4{PzN7IN88US=>	MYTTRW5ITVJ?
TE-5	NIPYUlZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MoLkTWM2OD1{MD63OFgzKM7:TR?=	NWmwUGZnW0GQR1XS
IST-SL1	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWfJR\|UxRTJyLke4O\|kh\|ryP	NFroc3VUSU6JRWK=
A375	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXnJR\|UxRTJzLkC1Olch\|ryP	M165T3NCVkeHUh?=
MC116	M3;kS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWPDd4VzUUN3ME2yNU4xPzJ\|IN88US=>	NEm5O5lUSU6JRWK=
GI-1	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUXRZ\|RnUUN3ME2yNU4yPyEQvF2=	MUPTRW5ITVJ?
HOP-62	NWfyN3VNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1\4cmlEPTB;MkGuNlc5PCEQvF2=	NYH1XHhyW0GQR1XS
PA-1	NV\yR2hqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUjwfVJ5UUN3ME2yNU4zPzh5IN88US=>	NEXTbm1USU6JRWK=
HT	NILhN3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1zJXWlEPTB;MkGuOFM{OSEQvF2=	NFzaXZpUSU6JRWK=
HUTU-80	Ml\qS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVrJR\|UxRTJzLkSzN\|Yh\|ryP	M1rvVXNCVkeHUh?=
NCI-H1975	Mk\aS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXXJR\|UxRTJzLkS2NUDPxE1?	NXPHXlZmW0GQR1XS
GAK	MlLTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYDJR\|UxRTJzLkS5PUDPxE1?	Mn24V2FPT0WU
SK-N-AS	MnPuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1jOUmlEPTB;MkGuOVYyQSEQvF2=	NIThSZBUSU6JRWK=
OE33	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWDJR\|UxRTJzLk[wOFYh\|ryP	NGrYeGFUSU6JRWK=
YKG-1	NYLVO215T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NH3IOGpKSzVyPUKxMlY2PDVizszN	NYHVVZVSW0GQR1XS
CAL-85	MmnES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MX7JR\|UxRTJzLkmzNFUh\|ryP	NH[5cGRUSU6JRWK=
NCI-H2347	M1\DOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4LKe2lEPTB;MkGuPVQzQCEQvF2=	MmDtV2FPT0WU
PANC-08-13	MmHwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NImzeVZKSzVyPUKyMlAyOTlizszN	NXG3dWNxW0GQR1XS
SK-N-FI	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NELydZpKSzVyPUKyMlMxPzRizszN	NXrGeVlXW0GQR1XS
NEC8	MlTqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3nWcWlEPTB;MkKuOVA4QCEQvF2=	MWXTRW5ITVJ?
AN3-CA	M13pO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlXFTWM2OD1{Mj62NFg1KM7:TR?=	M{DKeHNCVkeHUh?=
HuO9	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NF\zZ3RKSzVyPUKyMlc{QTZizszN	NGTRdmtUSU6JRWK=
COLO-800	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWDEfFdxUUN3ME2yNk44PjV\|IN88US=>	NXLpTpNRW0GQR1XS
HT-29	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NF3tVpVKSzVyPUKyMlg5OjNizszN	MnfaV2FPT0WU
OC-314	M{G3S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NI[4OIdKSzVyPUKyMlg5PDVizszN	MXrTRW5ITVJ?
G-401	NXnrUI1oT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4S1fmlEPTB;MkOuNFQ3OiEQvF2=	M1zGc3NCVkeHUh?=
Saos-2	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWfJR\|UxRTJ\|LkWxPFIh\|ryP	NELKSm9USU6JRWK=
UACC-62	NUnDVINtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYfJR\|UxRTJ\|LkW4N\|Mh\|ryP	M2\sSHNCVkeHUh?=
D-247MG	Ml3XS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVnuWo42UUN3ME2yN{44QTN7IN88US=>	M1\YZXNCVkeHUh?=
COLO-741	M{DsXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYLsbWZMUUN3ME2yN{46PTZ3IN88US=>	NEfFWZdUSU6JRWK=
ES3	M4PxS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWn3fpRXUUN3ME2yOE4xODJ\|IN88US=>	NGTvRo1USU6JRWK=
LNCaP-Clone-FGC	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1LyVmlEPTB;MkSuNFIyOSEQvF2=	NGHNWotUSU6JRWK=
SW1710	NV3Jb41ZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVG0W2FGUUN3ME2yOE4yPTB4IN88US=>	MYrTRW5ITVJ?
LU-99A	NGLpS2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYXJR\|UxRTJ2LkG4OFEh\|ryP	NGrIc5lUSU6JRWK=
HOP-92	NGLxNnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MkCyTWM2OD1{ND63NlUh\|ryP	NFKzWXlUSU6JRWK=
LS-123	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXnzOnB2UUN3ME2yOE46PjF2IN88US=>	MYHTRW5ITVJ?
T84	M2PnPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MkntTWM2OD1{ND65O\|Y2KM7:TR?=	MWLTRW5ITVJ?
HCT-116	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWfJR\|UxRTJ3LkSxPFYh\|ryP	M3\Dc3NCVkeHUh?=
M14	NEW5O2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Ml3ETWM2OD1{NT60OFQ4KM7:TR?=	MknRV2FPT0WU
OCUB-M	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVXmbY5ZUUN3ME2yOU41PDV4IN88US=>	NYH3RWJtW0GQR1XS
MKN45	NFvFc3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{C1WGlEPTB;MkWuOlMyPSEQvF2=	MkfkV2FPT0WU
LCLC-97TM1	NY\4XlFyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWrJR\|UxRTJ3LkeyPFUh\|ryP	M1LOZXNCVkeHUh?=
RVH-421	NEXzd2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHvTZZNKSzVyPUK1MlgyPjFizszN	NIS1OZJUSU6JRWK=
NKS-81-FD	MlTCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmfUTWM2OD1{NT65NFIyKM7:TR?=	NFLLV3dUSU6JRWK=
NCI-H596	MmmzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFLyfIdKSzVyPUK2MlA1QDdizszN	MkKyV2FPT0WU
GB-1	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NX\mcGFrUUN3ME2yOk4yQDd7IN88US=>	NVHHfHJGW0GQR1XS
ZR-75-30	NIrQeY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYXJR\|UxRTJ4LkKyPVch\|ryP	MWDTRW5ITVJ?
U-2-OS	NFvQU\|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mo[wTWM2OD1{Nj6zO\|U4KM7:TR?=	NWq5dnlwW0GQR1XS
HuP-T3	Ml7NS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NV\UW\|RDUUN3ME2yOk43OTB{IN88US=>	MVrTRW5ITVJ?
MOLT-16	NGDqW4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUjJR\|UxRTJ4Lk[xOlYh\|ryP	Mle0V2FPT0WU
U-87-MG	NULybohFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2Sx[mlEPTB;Mk[uO\|Q{QCEQvF2=	M{XWXnNCVkeHUh?=
8505C	NYPyNZptT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmHBTWM2OD1{Nj65NVI3KM7:TR?=	M1HKO3NCVkeHUh?=
SK-MEL-3	NXXkNnEyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2fUSWlEPTB;Mk[uPVgzQCEQvF2=	MWfTRW5ITVJ?
COLO-824	M{H5O2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnvWTWM2OD1{Nz6yNVk2KM7:TR?=	MX;TRW5ITVJ?
EW-1	NX3kPXpLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXrJR\|UxRTJ5LkO1OVQh\|ryP	NInQZWhUSU6JRWK=
UACC-257	NV\le4JGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MULJR\|UxRTJ5LkO4NFQh\|ryP	NFixeoxUSU6JRWK=
Hs-578-T	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1z1eWlEPTB;MkeuOVI6QSEQvF2=	MXnTRW5ITVJ?
UACC-893	NXm3PY9oT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYLJR\|UxRTJ5Lk[2N\|Eh\|ryP	MnnSV2FPT0WU
MHH-NB-11	NGT5eWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NILSfodKSzVyPUK3MlgxODdizszN	MWnTRW5ITVJ?
KYSE-410	M3TjPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mmm1TWM2OD1{OD6yO\|c6KM7:TR?=	M{jMeHNCVkeHUh?=
SF126	NI\6OW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MX;JR\|UxRTJ6Lke0N\|Uh\|ryP	MkfPV2FPT0WU
HT-144	MkPvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4DF[2lEPTB;MkmuN\|M3OiEQvF2=	MXjTRW5ITVJ?
SW1573	NWfaRodCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NH3ydWJKSzVyPUK5MlM2ODlizszN	MlXQV2FPT0WU
SW620	M3m5XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXzsRZBFUUN3ME2yPU4{PjRzIN88US=>	NUnsSndVW0GQR1XS
SCH	NHPXXXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NV;O[5BMUUN3ME2yPU45QDNzIN88US=>	NHjNS5NUSU6JRWK=
EW-22	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2LYWGlEPTB;M{CuNVk3QSEQvF2=	NWOzUVlOW0GQR1XS
H4	NUTiToQ5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXLtflloUUN3ME2zNE41PjV2IN88US=>	NIHMRZhUSU6JRWK=
CAS-1	M4XrO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVrJR\|UxRTNyLke4OVkh\|ryP	NX;3PXhsW0GQR1XS
MG-63	M4n1W2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1nwfGlEPTB;M{CuPFQ4QCEQvF2=	MUfTRW5ITVJ?
MDA-MB-415	NVTLU45nT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mk\VTWM2OD1\|MT6xO\|U{KM7:TR?=	M1XLTXNCVkeHUh?=
NCI-H1395	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUXJR\|UxRTNzLkKzNlgh\|ryP	MmPFV2FPT0WU
Ca-Ski	M3XJ[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIrQRXJKSzVyPUOxMlMyPzdizszN	NVLq[Hg1W0GQR1XS
BxPC-3	MlG3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHnKUG1KSzVyPUOxMlM4OjlizszN	MVrTRW5ITVJ?
A3-KAW	NWLzU45mT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHHHR41KSzVyPUOxMlQ1PzFizszN	NE[zOlVUSU6JRWK=
T-24	MlHNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYfJR\|UxRTNzLkezOlIh\|ryP	MorTV2FPT0WU
NCI-H2029	M{fIcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Ml\wTWM2OD1\|MT63O\|Y2KM7:TR?=	MV;TRW5ITVJ?
YAPC	M3q1WWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWHJR\|UxRTN{LkC0NFch\|ryP	M3nTU3NCVkeHUh?=
SK-MEL-2	M{W1PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3PG[GlEPTB;M{KuNFUzKM7:TR?=	MVjTRW5ITVJ?
LS-513	NYfV[GNYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NV[3[XJkUUN3ME2zNk4yOTh5IN88US=>	NWT2OFJvW0GQR1XS
AsPC-1	NVi3WZk2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFr3e4ZKSzVyPUOyMlM3ODVizszN	M4rYNHNCVkeHUh?=
KYSE-150	NXPaXVFDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWDJR\|UxRTN{LkO3O\|Mh\|ryP	NGXTWJRUSU6JRWK=
NCI-H520	NITYU\|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHzxN41KSzVyPUOyMlQ1QDJizszN	Ml3sV2FPT0WU
JEG-3	NGD2eFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUPROI8{UUN3ME2zN{4xQTdzIN88US=>	MXjTRW5ITVJ?
GMS-10	M4DSU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NEXl[W5KSzVyPUOzMlMxODRizszN	NYm4VFVMW0GQR1XS
HT-1080	Mo\WS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnyyTWM2OD1\|Mz6zPUDPxE1?	NYnkO4UxW0GQR1XS
NCI-H1651	NXP3XWlkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmLuTWM2OD1\|Mz6zPVYh\|ryP	MkXnV2FPT0WU
NCI-H2122	M{L5eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYnsW5hSUUN3ME2zN{42PTd2IN88US=>	NH3Mc2ZUSU6JRWK=
ES5	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mo\yTWM2OD1\|Mz63NlkzKM7:TR?=	NU\6VYJCW0GQR1XS
8305C	NEXM[2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGrSW3ZKSzVyPUOzMlk6OzdizszN	NUX3UGNzW0GQR1XS
KM12	NHOxV4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWfJR\|UxRTN2LkC0O\|gh\|ryP	MojUV2FPT0WU
HCT-15	MlnmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NV7iUHJRUUN3ME2zOE4yOjdizszN	NFywbFdUSU6JRWK=
OVCAR-5	MoXSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYDJR\|UxRTN2LkKxPFIh\|ryP	MnLYV2FPT0WU
NCI-H2291	Mln0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3Tlb2lEPTB;M{SuNlQ4OiEQvF2=	NIrjRXlUSU6JRWK=
CP50-MEL-B	NGrQdXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHXXNmpKSzVyPUO0MlY2QTJizszN	Mn\RV2FPT0WU
C-33-A	NYnhUpIyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NIH2WGVKSzVyPUO0MlY5PTdizszN	NX3IUWIyW0GQR1XS
NCI-H2452	NWrRNlF[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1vWTGlEPTB;M{SuO\|g5OiEQvF2=	M4iyOnNCVkeHUh?=
MDA-MB-157	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHjGcnNKSzVyPUO0MlgyQTNizszN	MkThV2FPT0WU
LN-405	NGTNbJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnT6TWM2OD1\|NT60N\|A5KM7:TR?=	MlzvV2FPT0WU
MDA-MB-231	NHfBb4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NH7uUopKSzVyPUO1MlUxPTRizszN	MkT6V2FPT0WU
EW-24	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1O3XGlEPTB;M{WuOlM{PSEQvF2=	M{jFfHNCVkeHUh?=
MKN28	M1rncGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYPJR\|UxRTN3LkiyN\|Yh\|ryP	M1POSXNCVkeHUh?=
KINGS-1	NEPleHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFvJSYNKSzVyPUO1Mlg1OzRizszN	NYHORZRNW0GQR1XS
LC-2-ad	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NIXLPJJKSzVyPUO2MlY6QSEQvF2=	MoixV2FPT0WU
IGR-1	MkOwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmHITWM2OD1\|Nj63NFc2KM7:TR?=	M{[xUHNCVkeHUh?=
SW626	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVzuNI9DUUN3ME2zO{4xPDF5IN88US=>	MWDTRW5ITVJ?
ONS-76	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{fv[mlEPTB;M{euNVMxQSEQvF2=	M{ezcXNCVkeHUh?=
T98G	NFmyS4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUjJR\|UxRTN5Lki2N\|Uh\|ryP	MlG2V2FPT0WU
NB14	M2HmcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1[wS2lEPTB;M{iuOFU1PCEQvF2=	NHLJbWhUSU6JRWK=
D-423MG	NVPndWI4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Ml[1TWM2OD1\|OD60PFY6KM7:TR?=	MkLNV2FPT0WU
NCI-H510A	NGi3OlVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWDsO\|hRUUN3ME2zPE43PDVzIN88US=>	MnrDV2FPT0WU
NMC-G1	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlG2TWM2OD1\|OD63NlIzKM7:TR?=	NGPXVmdUSU6JRWK=
SW948	NGfLXo5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MoT6TWM2OD1\|OD64PVQ6KM7:TR?=	NFvWXXJUSU6JRWK=
MFM-223	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MkLCTWM2OD1\|OD65OFMyKM7:TR?=	NGfi[ZdUSU6JRWK=
PAN1	NXHvfGo2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlS4TWM2OD1\|OD65PVE6KM7:TR?=	MlzPV2FPT0WU
MZ7-mel	NEfQbHNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYTPeWpFUUN3ME2zPU4yOTl7IN88US=>	MnzLV2FPT0WU
COLO-679	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGPmTZZKSzVyPUO5Mlk4ODhizszN	NFvBT2JUSU6JRWK=
SW872	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFX2U3hKSzVyPUSwMlIxOzFizszN	NEnJO5dUSU6JRWK=
HT-1197	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2fYWmlEPTB;NECuNlg3QSEQvF2=	NFHUWZFUSU6JRWK=
ES6	NUH6[npbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MX;JR\|UxRTRyLkS1OVIh\|ryP	M2rEcXNCVkeHUh?=
SNU-387	NW\FT\|lDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1vnNGlEPTB;NECuPFI{QCEQvF2=	NE\LT\|ZUSU6JRWK=
T47D	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NEC5foJKSzVyPUSxMlAyQTJizszN	M1TpNHNCVkeHUh?=
G-402	M4m1dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1j5bGlEPTB;NEGuNFgxQSEQvF2=	M2nGNHNCVkeHUh?=
MZ1-PC	NIq0UXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYfJR\|UxRTRzLkixJO69VQ>?	NGPyepJUSU6JRWK=
SW1417	M3XMW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGTXfYJKSzVyPUSyMlMxOyEQvF2=	Mn7aV2FPT0WU
RERF-LC-MS	M4LqPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVjETVV{UUN3ME20Nk42ODh5IN88US=>	M{T6SXNCVkeHUh?=
SF539	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MU\JR\|UxRTR{LkW1Nlkh\|ryP	MnzoV2FPT0WU
ESS-1	M3POUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3T1eWlEPTB;NEOuOVU2QCEQvF2=	NF\scVNUSU6JRWK=
RO82-W-1	M2X4[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGjoXpFKSzVyPUSzMlYyPTNizszN	M2jobHNCVkeHUh?=
S-117	M2PtR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mk\uTWM2OD12Mz62PVU5KM7:TR?=	NHrqeWZUSU6JRWK=
SW756	NE\SV4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NV\2TYpNUUN3ME20N{45OjR{IN88US=>	MY\TRW5ITVJ?
CP66-MEL	NGO2eJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3HHcmlEPTB;NEWuO\|E1OyEQvF2=	M4nDdXNCVkeHUh?=
H-EMC-SS	NEjwcpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MX;JR\|UxRTR3Lke2PVMh\|ryP	MYLTRW5ITVJ?
NCI-H2052	NF35RWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mk\BTWM2OD12NT65NFI4KM7:TR?=	MXHTRW5ITVJ?
SW684	NWLBUWJTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFz6XpJKSzVyPUS3MlAxQDFizszN	NW\5Vol5W0GQR1XS
HCC1569	MnLpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NIT3boVKSzVyPUS3MlE3PThizszN	M3LlXXNCVkeHUh?=
KGN	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mn63TWM2OD12Nz6zN\|EyKM7:TR?=	M1HWZ3NCVkeHUh?=
LCLC-103H	M1PRNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYS0[pIzUUN3ME20O{41PDB2IN88US=>	M4S3Z3NCVkeHUh?=
SW780	M2npW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVmyXndEUUN3ME20O{43OzVzIN88US=>	NV7WW2F6W0GQR1XS
NCI-H1703	NUfQe5NIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3zaVWlEPTB;NEiuN\|M2OiEQvF2=	M2jTN3NCVkeHUh?=
HCC1395	Mn\IS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUnJR\|UxRTR6Lke0N\|Ih\|ryP	NFHTOHRUSU6JRWK=

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	phospho-EGFR / phospho-ERK / phospho-SRC / phospho-AKT; PubMed: 22586683 Cancer Discov Effect of overexpressing CRKL on phosphorylation levels of EGFR, ERK, AKT and SRC in response to gefitinib. HCC827 cells expressing a control vector or CRKL were exposed to gefitinib at indicated concentrations for 6 h and cell lysates were collected for immunoblotting with indicated specific antibodies. Cyclin D1/ p16 / p27 / pRb; PubMed: 18559346 J Biol Chem levels of phosphorylated and total EGFR, IGF-1R, Akt, ERK1/2, and Rb and levels of cyclin D1, p27, p16, and actin following 6- or 16-h treatment of A431 cells with combinations of 1 or 3 μm gefitinib and 3 μm NVP-ADW742. Data are representative of two independent experiments. uc-caspase-9 / c-caspase-9 / uc-caspase-3 / c-caspase-3 / uc-PARP / PARP; PubMed: 23102728 Mol Oncol Apoptosis resulting from combined treatment with gefitinib and an MEK inhibitor. (A) apoptosis relating protein induced by gefitinib and/or AZD6244 in PC‐9/wt and PC‐9/gef B4 cells. (B) Apoptosis relating protein induced by gefitinib and/or CI‐1040 in PC‐9/wt and PC‐9/gef B4 cells. (C) apoptosis relating protein induced by gefitinib and/or AZD6244 in PC‐9/gefE3 and PC‐9/gefE7 cells. (D) apoptosis relating protein induced by gefitinib and/or CI‐1040 in PC‐9/gefE3 and PC‐9/gefE7 cells. PPAR-γ; PubMed: 23409107 PLoS One Fold increase relative to control was determined after normalization with β-actin as external loading control.	22586683 18559346 23102728 23409107
Immunofluorescence	EGFR / LC3; PubMed: 31196210 J Exp Clin Cancer Res H157 and H1299 cells were treated with gefitinib, or curcumin alone, or gefitinib plus curcumin at indicated concentration for 48 h and then were fixed with methanol, immunostained with anti-EGFR (green), anti-LC3 (red), and DAPI (blue), and analyzed by confocal microscopy to determine the intracellular locations of EGFR and LC3. PPAR-γ; PubMed: 23409107 PLoS One Upregulation and nuclear accumulation of PPARγ following treatment with gefitinib (24 hs). p-EGFR / β-catenin; PubMed: 23461856 FEBS J In untreated CNE2 cells, β-catenin was located in cytoplasmic membranes and cytoplasm. Treatment with EGF (50 ng/mL) resulted in increased β-catenin nuclear staining, which was reversed by either gefitinib (1 μM) or LY294002 (15 μM).	31196210 23409107 23461856
Growth inhibition assay	GI50; PubMed: 23409107 PLoS One Dose-response of bladder cancer cell lines to EGFR inhibitor (gefitinib). The GI50 value was defined as the mean concentration of drug that generates 50% of growth inhibition as compared to controls.	23409107

In vivo

Gefitinib (100 mg/kg) improves the anti-tumor effect of radiotherapy in LoVo tumor xenografts. ^[3] Gefitinib treatment of nude mice bearing established human GEO colon cancer xenografts reveals a reversible dose-dependent inhibition of tumor growth because GEO tumors resumes the growth rate of controls at the end of the treatment. ^[4]

Protocol

Cell Research:^[1]

- Collapse

Cell lines: NR6, NR6M and NR6W cells
Concentrations: 0-2 μM
Incubation Time: 72 hours
Method: Exponentially growing cells including NR6, NR6M, NR6M and NR6W cells are seeded in sextuple in 96-well plates at a concentration of 2000 cells/well, allowed to adhere and subsequently washed in PBS and incubated overnight in medium containing 0.5% FCS. Cells are then treated with varying concentrations (0-2 μM) of Gefitinib or the solute control DMSO and EGF. The optimal EGF concentration for inducing proliferation of NR6wtEGFR and NR6W cells has previously been determined and hence NR6wtEGFR and NR6W cells are supplemented with 10 nM and 0.1 nM EGF, respectively. EGF is not added to NR6 and NR6M cells. After 72 hours the amount of cells are measured by performing a MTT proliferation assay.
(Only for Reference)

Animal Research:^[3]

- Collapse

Animal Models: Female nude mice (cba nu/nu) aged 8–10 weeks are intra-dermal injected with LoVo cells.
Dosages: 100 mg/kg
Administration: Once daily by oral administration (0.1 mL/10 g body weight) for 14 days
(Only for Reference)

References

- Collapse

Solubility (25°C)

In vitro	DMSO	89 mg/mL (199.14 mM)
	Ethanol	4 mg/mL (8.95 mM)
	Water	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 1% CMC Na For best results, use promptly after mixing.	30mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Gefitinib (ZD1839) SDF

Molecular Weight	446.90
Formula	C₂₂H₂₄ClFN₄O₃
CAS No.	184475-35-2
Storage	3 years-20°C powder 2 years-80°C in solvent
Synonyms	N/A
Smiles	COC1=C(OCCCN2CCOCC2)C=C3C(=NC=NC3=C1)NC4=CC=C(F)C(=C4)Cl

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage

mg/kg

Average weight of animals

Dosing volume per animal

Number of animals

Step 2: Enter the in vivo formulation (Different batches have different solubility ratios, please contact Selleck to provide you with the correct ratio)

% DMSO+ % + % Tween 80+ % ddH₂O

Calculate Reset

Calculation results:

Working concentration： mg/ml；

Method for preparing DMSO master liquid: ： mg drug pre-dissolved in μL DMSO (Master liquid concentration mg/mL， Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation：Take DMSO master liquid, next addμL PEG300， mix and clarify, next addμL Tween 80，mix and clarify, next add μL ddH₂O，mix and clarify.

Note：1.Please make sure the liquid is clear before adding the next solvent.
2.Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2020-05-15)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT03292133	Recruiting	Drug: EGF816\|Drug: Gefitinib	Lung Cancer	Massachusetts General Hospital\|Novartis	October 31 2017	Phase 2
NCT03122717	Recruiting	Drug: Gefitinib\|Drug: Osimertinib	Non-Small Cell Lung Cancer	Dana-Farber Cancer Institute\|AstraZeneca	May 9 2017	Phase 1\|Phase 2
NCT02932345	Completed	--	EGFR Mutation Positive Advanced Non-small-cell Lung Cancer	AstraZeneca	October 31 2016	--
NCT02824458	Recruiting	Drug: Apatinib\|Drug: Gefitinib\|Drug: Placebo	EGFR Tyrosine Kinase Inhibitors Plus VEGFR Inhibitors	Sun Yat-sen University	June 2016	Phase 3
NCT02804100	Unknown status	--	Carcinoma Non-Small-Cell Lung\|Bronchial Neoplasms\|Carcinoma Bronchogenic\|Lung Diseases\|Lung Neoplasms	Wenzhou Medical University	May 2016	--

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
I try to dissolve Gefitinib (ZD1839) in 0.5% methylcellulose+0.2% Tween 80 for in vivo experiments. However, when I prepare the mixture, it forms precipitates. Exists another way to dissolve completely the compound?
Answer:
S1025 can be dissovled in both 5% DMSO+corn oil and 5% DMSO+30% PEG 300+5% Tween 80+ddH2O at 2.5 mg/ml clearly. It dissolves in DMSO not readily, please sonicate and warm it in water bath at about 45 degree, and dissolve it clearly first. Then add other solvent.

EGFR Signaling Pathway Map

EGFR Inhibitors with Unique Features

Pan EGFR Inhibitor

AZD8931 (Sapitinib) : Pan-ErbB inhibitor, EGFR/ErbB2/ErbB3, IC50=4 nM/3 nM/4 nM.
Most Potent EGFR Inhibitor

Afatinib (BIBW2992) : EGFR(wt), IC50=0.5 nM; EGFR(L858R), IC50=0.4 nM; EGFR(L858R/T790M), IC50=10 nM; HER2, IC50=14 nM.
FDA-approved EGFR Inhibitor

Lapatinib : Approved by FDA for breast cancer.
Newest EGFR Inhibitor

CO-1686 (AVL-301) ^New : Irreversible, mutant-selective EGFR inhibitor with K_i of 21.5 nM and 303.3 nM for EGFRL858R/T790M and EGFRWT, respectively.

Related EGFR Products

Erlotinib ^New

Erlotinib is an EGFR inhibitor with IC50 of 2 nM, >1000-fold more sensitive for EGFR than human c-Src or v-Abl. Erlotinib induces autophagy.
Afatinib (BIBW2992) Dimaleate ^New

Afatinib (BIBW2992) Dimaleate irreversibly inhibits EGFR/HER2 including EGFR(wt), EGFR(L858R), EGFR(L858R/T790M) and HER2 with IC50 of 0.5 nM, 0.4 nM, 10 nM and 14 nM, respectively; 100-fold more active against Gefitinib-resistant L858R-T790M EGFR mutant.
Poziotinib (HM781-36B) ^New

Poziotinib (HM781-36B) is an irreversible pan-HER inhibitor with IC50 of 3.2 nM, 5.3 nM and 23.5 nM for HER1, HER2, and HER4, respectively. Poziotinib also induces apoptosis and G1 cell cycle arrest. Phase 2.
Erlotinib HCl (OSI-744)

Erlotinib HCl (OSI-744) is an EGFR inhibitor with IC50 of 2 nM in cell-free assays, >1000-fold more sensitive for EGFR than human c-Src or v-Abl.
Afatinib (BIBW2992)

Afatinib (BIBW2992) inhibits EGFR/ErbB irreversibly in vitro with IC50 of 0.5, 0.4, 10, 14, 1 nM for EGFR^wt, EGFR^L858R, EGFR^L858R/T790M ErbB2 (HER2) and ErbB4 (HER4), respectively. Afatinib induces autophagy.
Osimertinib (AZD9291)

Osimertinib (AZD9291) is an oral, irreversible, and mutant-selective EGFR inhibitor with IC50 of 12.92, 11.44 and 493.8 nM for Exon 19 deletion EGFR, L858R/T790M EGFR, and WT EGFR in LoVo cells, respectively. Phase 3.
Lapatinib

Lapatinib, used in the form of Lapatinib Ditosylate, is a potent EGFR and ErbB2 inhibitor with IC50 of 10.8 and 9.2 nM in cell-free assays, respectively. Lapatinib induces ferroptosis and autophagic cell death.
AG-490 (Tyrphostin B42)

AG-490 (Tyrphostin B42) is an inhibitor of EGFR with IC50 of 0.1 μM in cell-free assays, 135-fold more selective for EGFR versus ErbB2, also inhibits JAK2 with no activity to Lck, Lyn, Btk, Syk and Src.
Rociletinib (CO-1686)

Rociletinib (CO-1686, AVL-301) is an irreversible, mutant-selective EGFR inhibitor with K_i of 21.5 nM and 303.3 nM for EGFR^L858R/T790M and EGFR^WT in cell-free assays, respectively. Phase 2.
AG-1478 (Tyrphostin AG-1478)

AG-1478 (Tyrphostin AG-1478) is a selective EGFR inhibitor with IC50 of 3 nM in cell-free assays, almost no activity on HER2-Neu, PDGFR, Trk, Bcr-Abl and InsR.

Choose Your Country or Region

By Signaling Pathways

By product type

Gefitinib (ZD1839)